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Diarylheptanoids are a family of plant metabolites with a characteristic structure of two 
hydroxylated aromatic rings attached by a linear seven-carbon chain. Diarylheptanoids 
have mostly been isolated from plants belonging to the Zingiberaceae family. The South 
African medicinal plant Siphonochilus aethiopicus, more commonly known as 
‘wild ginger’, also belongs to the Zingiberaceae family. One of the compounds isolated 
from this plant it a novel diarylheptanoid.  In this study, the synthesis of this novel 
diarylheptanoid will be investigated. 
The targeted diarylheptanoid has two substituted phenyl rings attached by a seven-carbon 
aliphatic chain with two sterogenic centers and a carbon-carbon double bond. Osmium-
catalysed asymmetric dihydroxylation was used to generate the two stereogenic centres. 
The Horner Wadsworth-Emmons (HWE) reaction was investigated, in order to generate 
the trans-double bond on the seven carbon aliphatic chain. HWE reaction is a trans-
selective reaction leading to the formation of only the desired isomer.  
The synthetic strategy used for the synthesis of the targeted diarylheptanoid is the 
C2-moiety + C5-moiety strategy. The C2-moiety is the phosphonate ester and the C5-moiety 
is the aldehyde for the HWE reaction. In this investigation we were able to successfully 
synthesis the required C2-moiety and the C5-moiety. Both the precursors were synthesised 
from commercially available starting materials, utilising functional group transformation 
reactions. However, modifications to the C5-moiety were made due to its instability under 
the HWE reaction conditions.  When the C5-moiety was an aldehyde, decomposition was 
seen under HWE reaction conditions. Thus the C5-moiety was converted to the 
corresponding lactol and then subjected to the HWE reaction. Nevertheless, this reaction 
was not successful, thus we were not able to couple the two precursors to form the desired 
seven-carbon aliphatic chain. 
Even though the targeted diarylheptanoid was not successfully synthesised, the synthetic 
route developed in this investigation is not only viable to the target compound but is also 
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The term ‘natural product’ refers to secondary metabolites that are derived from natural 
sources such as plants, animals and microorganisms1. Secondary metabolites are 
compounds unique to a specific organism and are often produced by living organisms for 
the purpose of defence, communication and predation2. The role of natural products as 
medicines has been enormous throughout human evolution. It has been documented that 
our earliest ancestors chewed on certain herbs to relieve pain and wrapped leaves around 
wounds to facilitate healing3.  
Even though medicinal plants were used widely in Orient and Occident medicinal systems, 
their active components remained unknown until the eighteenth and nineteenth centuries3. 
The advent of modern chemistry opened a new era for natural products and their use in the 
pharmaceutical industry. Morphine from opium was the first naturally derived medicine 
and the first to be commercialised in 18263. Natural product discovery efforts kick started 
after the large scale production of penicillin, isolated from the mould Penicillium notatum 
during World War II1. Some well-known compounds that were isolated from natural 
products include salicin from Salix alba, quinine from Cinchona ledgeriana, caffeine from 
Coffea arabica, nicotine from Nicotiana tabacum and cocaine from Erythroxylum coca1, 3, 
4. 
 
1.1.2 Decline of natural product research in the pharmaceutical industry 
 
Natural product research in industry decreased drastically in the early 1990s and the early 





synthesis of natural products on industrial scale at an acceptable cost4. Also, the advent of 
combinatorial chemistry and high-throughput screening to generate and identify new drug 
candidates made natural products less attractive3, 4. However, combinatorial chemistry did 
not give the anticipated outcome in terms of new drug candidates. In 2007, only 17 new 
drug candidates were approved compared to 1998, when a total of 53 drugs were 
approved3. Despite the decrease in natural product research, drugs derived from natural 
products still bring in a significant revenue for many of the major pharmaceutical 
companies1. For example, drugs such as Lipitor® and Pravachol®, which are natural 
product-inspired drugs, continue to produce multi-billion dollar revenue1. 
 
1.1.3 Natural products as sources of new drugs 
 
Natural product compounds hold great promises for finding better and new drugs since 
they are a source of novel leads and an inspiration for the synthesis of non-natural 
molecules with improved pharmacological and pharmaceutical properties. Natural 
products from plants are highly potent and selective as a result of evolutionary selection1. 
Thus they are ideal lead compounds for the development of therapeutic agents for 
oncology and infectious diseases. Approximately 25% of all prescription medicines and 
60% of anti-cancer drugs on clinical trials at the end of 2005 were of plant oringin2, 5, 6.  
Drugs based on natural products include compounds isolated from plants, microbial 
fermentation, marine, synthetic and semi-synthetic compounds based on natural products. 
Amongst the natural product sources, plants and microbials have been the major sources of 
lead compounds4. Even so, it has been reported that the percentage of plants and 
microorganisms that have been screened for bioactivity, is relatively small4. Thus, more 
extensive screening of these rich natural product resources could provide far more novel 




Plant from the Zingiberaceae (ginger family) have been used for centuries as foods, spices, 





Zingiber officinale (ginger), Curcuma longa (curcuma) and Alpinia blepharocalyx7. 
Chemical investigations of plants belonging to this family have led to the isolation of a 
large number of biologically active compounds. Two major groups of biologically active 
compounds that have been isolated from the Zingiberaceae include gingerol-related 
compounds and diarylheptanoids7, 9. Diarylheptanoids have mainly been isolated from 
Curcuma and Zingiber species. Amongst the diarylheptanoids that have been isolated from 
these plants, curcumin (1) is one of the most well-known compounds.  
 
1.2.1 Curcuma species 
 
Curcumin (1), the major orange pigment found in turmeric (Curcuma longa) rhizomes was 
the first diarylheptanoid isolated in 1815 and its structure determined in 191010. Ever since, 
varieties of diarylheptanoids have been isolated from different species of Curcuma. Since 
the discovery of curcumin (1), various natural analogues and metabolites of curcumin have 
been isolated from turmeric11. Curcumin (1), demethoxycurcumin (2) and 
bisdemethoxycurcumin (3) are the three most important analogues from turmeric and are 
collectively known as curcuminoids11. Scheme 1.1 shows some of the diarylheptanoids 
that were isolated from Curcuma longa. Furthermore, Ishidha and co-workers12 isolated 
and characterised cyclic diarylheptanoids (4-8) from the Curcuma longa and Suksamrarn 
et al.13 isolated three new diarylheptanoids and nine known diarylheptanoids from the 












































































 (4) R1= OH, W= C=O, X=H 
 (5) R1= OCH3, W= H, X= C=O  
(7) Z= C-OH 
(8) Z= C=O 
(6)
 
Figure 1.1: Cyclic diarylheptanoids isolated from Curcuma longa 
 
1.2.2 Zingiber officinale 
 
Numerous chemical investigations of Zingiber officinale, have led to the isolation of a 
wide variety of diarylheptanoids. From the rhizomes of Zingiber officinale, Kikuzaki et al. 
isolated five new diarylheptanoids14 (9-11). In addition to this, Liu and co-workers isolated 
several different diarylheptanoids, both linear and cyclic, from the rhizomes of this plant8, 
15 (12-14).  
                                                

























(9)   R1= Ac, R2 = H 
(10) R1=  R2 = H 
(11) R1= H, R2 = CH3 
(12) R1= R2= R3= R4= H 
(13) R1= R2=  R4= H, R3= OCH3
(14) R1= R2= R4= Ac, R3= H,
 
Figure 1.2: Diarylheptanoids from Zingiber officanale 
 
1.2.3 Siphonochilus aethiopicus 
 
 The South-African medicinal plant Siphonochilus aethiopicus B.L., more commonly 
known as wild ginger, is a forest floor plant with aromatic rhizomes. The generic name 
Siphonochilus is derived from the Greek siphon, meaning tube, and chilus, meaning lip in 
reference to the shape of the flower. The specific name ethiopicus means from southern 
Africa. African wild ginger is deciduous with hairless leaves, a cone-shaped rhizome, pink 
flowers and annually sprouts from underground stems in spring.  
 
Figure 1.3: African wild ginger† 
African Wild ginger has a long history of use in African traditional medicine and thus has 
been over harvested from the forests leading to its extinction16. The aromatic rhizomes of 
                                                
†





this plant are used to relieve colds, coughs, influenza, menstrual pain and several other 
illnesses16-18. Furthermore, the rhizomes of the South African wild ginger are known to 
exhibit natural anti-inflammatory activities16. 
Even though the African wild ginger is famous for its medicinal properties, only a limited 
number of studies have been done on this plant. So far no comprehensive taxonomical 
studies have been done on the genus Siphonochilus and thus exact distribution of this plant 
in Africa is poorly known.  From the studies conducted by Van Wyk16and Holzapfel et 
al.18, it has been found that the major chemical constituents of this plant are 
sesquiterpenoids of the furanoid type. The essential oil of this plant contains a high 
concentration of a single compound referred to as Siphonochilus sesquiterpenoid or 
siphonochilone16 (15). In addition to this diarylheptanoids (16) has also been isolated from 










1.3 Aim of this Investigation 
The aim of this study is the total synthesis of a novel diarylheptanoid isolated from the 
South African medicinal plant Siphinochilus aethiopicus (Wild ginger)19. The absolute 
stereochemistry of the isolated diarylheptanoid 16 has not been established, thus we aim at 
synthesising the isomer 17 with known relative and absolute stereochemistry. Furthermore, 
the developed synthetic method should be versatile, so that it could allow for the synthesis 
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Diarylheptanoids are a family of plant secondary metabolites which have shown to exhibit 
a variety of biological activities. Diarylheptanoids have mainly been isolated from plants 
belonging to the Zingiberaceae family, as outlined in Chapter 1.  The aim of this chapter is 




Diarylheptanoids are a family of plant metabolites based on 1,7-diphenylheptane with a 
characteristic structure of two hydroxylated aromatic rings attached by a linear seven 
carbon chain1,2. Their structures are classified into linear (I) and cyclic types. The latter is 
further subdivided into three main groups, meta,meta-biarylmacrocycles (II)  and meta, 
para-cylclophane (III) 2 and tetrahydropyrans (IV) . Linear diarylheptanoids are the 
biogenetic precursors of the macrocyclic diarylheptanoids and can be formed by phenolic 
oxidative coupling of the corresponding linear one1. Such coupling may lead via C-C 
coupling or C-O coupling to form type (II)  or type (III)  diarylheptanoids, respectively3. 
Linear diarylheptanoids are found in various monocotyledon and dicotyledon plant species 
and more than 70 different linear diarylheptanoids have been isolated from various plants4.
The most well-known linear diarylheptanoid is curcumin (1), which was isolated from 
turmeric (Curcuma longa). Turmeric belongs to Zingiberaceae family of plants which are a 
very rich source of diarylheptanoids. Cyclic diarylheptanoids have been isolated from 
various plant species. In 1995, Kikuzaki and Nakatani isolated five cyclic diarylheptanoids 
from the rhizomes of Zingiber officinale5. In 1976, Nagumo et al.6 isolated acerogenin 





compounds with an endocyclic biaryl ether bond have been isolated and identified from 


















Figure 2.1. Types of diarylheptanoids7* 
 
2.3 Phytochemistry of Diarylheptanoids 
 
Diarylheptanoids have mainly been isolated from Curcuma, Zingiber, Alnus, Alpinia and 
Acer species belonging to the family of gingers (Zingiberaceae), and from Centrolobium4. 
Diarylheptanoids isolated from Curcumin species and Zingiber officinale have been 
discussed in Chapter 1. In this section the focus will be given to diarylheptanoids that have 
been isolated from Alpinia, Acer and Alnus species. 
 
2.3.1 Alpinia species 
 
A variety of diarylheptanoids have also been isolated from the seeds of Alpinia 
blepharocalyx (Zingiberaceae). Both linear and cyclic diarylheptanoids have been isolated 
from the A. blepharocalyx4. Figure 2.2 shows some of the diarylheptanoids that were 
isolated from A. blepharocalyx. Dong et al.8 isolated a variety of diarylheptanoids from the 
seeds of A. blepharocalyx which showed antiplatelet activity (18 - 23). In addition to this, 
                                                            





a new family of diarylheptanoids, calyxins (24 - 25), was also isolated from the seeds of 
A. blepharocalyx9. Calyxins (24 - 25) are cyclic diarylheptanoids with a 2,4,6-cis
trisubstituted tetrahydropyran ring in their structure. Blephacocalyxins (24) was the first 
examples of a dimeric diarylheptanoid wherein the two diarylheptanoids are directly 





































Figure 2.2.  Diarylheptanoids isolated from Alpinia blepharocalyx 
 
2.3.2 Acer nikoense 
 
Acer nikoense (Zingiberaceae) has proven to be a rich source of diarylheptanoids, over the 





al.6 isolated acerogenin variants (26 - 27) from the bark of A. nikoense. Furthermore, 
Akazawa et al.10 isolated new cyclic diarylheptanoids named acerosides (28) and 












(28) R= H, R1= OH
(29) R= Glucose, R1= H
 
Figure 2.3. Diarylheptanoids from Acer nikoense 
 
2.3.3 Alnus species 
 
Alnus species have been found to be a rich source of diarylheptanoids. Amongst this 
species, A. japonica is one of the richest sources of diarylheptanoids. Kuroyanagi et al.11 
and Choi et al.12 isolated a variety of diarylheptanoids from the bark of A. japonica 





















R= β-D-Glucosyl or  β-D-Xyloside or H
 






2.4 Biological Activities of Diarylheptanoids Isolated from 
Various Plants 
 
Plants species known to contain diarylheptanoids are widely used in traditional medicine. 
Some examples of such plants include; Curcuma longa rhizomes which are widely used in 
traditional Asian medicine for the treatment of various diseases including hepatic disorder 
and rheumatism14; Alpinia blepharocalyx, seeds of which are used for the treatment of 
stomach disorders in Chinese medicine9; bark of Alnus japonica has been used for fever, 
hemorrhage, diarrhoea, gastroenteric disorder and cancer in oriental traditional medicine12. 
Diarylheptanoids have been found to possess a broad range of potent biological activities.  
Curcumin (1), amongst the diarylheptanoids, is the most well known, for its biological 
activities. Curcumin (1) has been found to exhibit biological activities such as anti-
inflammatory, anti-oxidative and anti-carcinogenic activities1, 15-17. In spite of its efficacy, 
curcumin (1) has not yet been approved as a therapeutic agent because of its poor aqueous 
solubility, low bioavailability and its intense staining colour. Several biological activities 
of diarylheptanoids characteristic of Alnus species have been reported. These include anti-
oxidative activity, nitric oxide synthase inhibitory activity18, melanogenesis inhibitory 
activity10, free radical scavenging activities10, anti-inflammatory effects and cytotoxic 
activities12. Diarylheptanoids isolated from the Chinese ginger (Zingiber officinale) have 
also been found to have cytotoxic and apoptotic activities19. Furthermore, diarylheptanoids 
from Acer nikoense have been shown to be inhibitors of nitric oxide production18 a d 
melanogenesis10. The diarylheptanoids isolated from Alpinia officinarum have shown 
promising inhibitory and bacterial activity against enteropathogenic Escherichia coli20 and 
diarylheptanoids from Alpinia blepharocalyx have shown anti-platelet activity8. 
 
2.4.1 Structure–activity correlation of biologically active 
diarylheptanoids 
 
Structural variations in any biologically active compound is important because altering its 
structure could lead to changes in physiological activity and its pharmacokinetics, i.e. how 





active compound is isolated from natural sources, extensive structure-activity relationship 
studies are carried out in order to optimize its potency and to define a drug profile for the 
compound. 
 
2.4.1.1 Antioxidative activity 
 
It has been found that the o-methoxy substituents on curcumin (1) and its analogues play a 
role in their potency as antioxidants. Anand et al17 reported that curcumin has better 
radical scavenging and antioxidant ability than the other two analogues of which 
demethoxycurcumin (DMC) (2) shows better activity than bisdemethoxycurcumin 
(BDMC) (3). Curcumin (1), DMC (2) and BDMC (3) differ in their chemical structure 
only by methoxy substitution (Scheme 1.1); curcumin has two methoxy groups, one on 
each phenyl group but DMC (2) has only one methoxy group on one of the phenyl groups 
where as BDMC (3) does not contain a methoxy group. In spite of the similar structures, 
the three analogues exhibit significantly different antioxidant activity. Anand and 
coworkers propose that the hydrogen bonding interaction between the phenolic OH and the 
o-methoxy group of curcumin influences the O-H energy and H-atom abstraction by 
free-radicals thus making it a superior free radical scavenger compared to BDMC17. 
Kuroyanagi and co-workers studied the antioxidative activity of the diarylhepatanoids 
isolated from Alnus japonica11. From their study it was found that linear diarylheptanoids 
containing two 3,4-dihydroxyphenyl moieties showed potent activity whereas compounds 
having a 3,4-dihydroxyphenyl and a 4-hydroxyphenyl moiety showed moderate activity 
and compounds  having two 4-hydroxyphenyl moieties showed no activity11. Based on 
these results, it can be concluded that the catachol structure of the diarylheptanoids is 




Chio et al.12 studied the variation in cytotoxic activity amongst the diarylheptanoids which 
were isolated from the bark of Alnus japonica. From their studies, it was found that 





compounds with only an enol moiety12. Furthermore, it was found that the presence of one 
OH group on the aromatic ring improved the cytotoxic activity against murin B16 
melanoma cells and SNU-1 gastric cancer cells, of the diarylheptanoid12. 
Yokosuka and his group also studied the cytotoxic activity of the diarylheptanoids which 
were isolated form Tacca chantriei21. These studies showed that the diarylheptanoids with 
three or four phenolic groups, for example compound 20, exhibit moderate cytotoxic 
activity against HL-60 human promyelocytic leukaemia and HSC-2 human oral squamous 
carcinoma cells, while diarylheptanoids with two phenolic OH groups (19) did not show 
significant activity. Furthermore, diarylheptanoids (21) with hydroxyl groups fully masked 
with methoxy groups also showed significant cytotoxic activity. Based on these results, 
Yokosuka et al. drew the conclusion that the number of hydroxyl groups on the biphenyl 
rings of the diarylheptanoids contribute to the cytotoxicity of the compounds21. 
 
2.4.1.3 Platelet inhibition activity 
 
Dong et al.8 studied the variation of antiplatelet activity of diarylheptanoids, isolated from 
Alpinia blepharocalyx (Figure 2.5). Platelet aggregation is induced by collagen, 
arachidonic acid (AA), adenosin diphosphate (ADP) and ristocetin. From this study it was 
found that compound 35 showed strong platelet inhibition activity caused by all four 
inducers as compared to compound 36, which showed activity against AA induced platelet 
aggregation8. The only difference in the structure of compound 35 and 36 is the presence 
of a hydroxy group at C-4’ position of the benzene ring in 35. Compound 37 and 38 both 
were found to be active against AA induced platelet aggregation8. Thus the structural 



























(34) R1= H, R2= OH, R3= H, R4= OH
(35) R1=  R2= R3=  R4= OH
(36) R1=  R2= R3=  R4= OCH3
(37) R1= OH, R2= H
(38) R1=  R2= OH
(39) R1=  R2= OCH3
 
Figure 2.5. Diarylheptanoids isolated from Alpinia blepharocalyx 
 
2.5 Synthesis of Diarylheptanoids 
 
Even though the structural complexity of most natural products makes their synthesis 
challenging, numerous natural products have been successfully synthesised. Since the 
discovery of diarylheptanoids, various diarylheptanoids and their analogues have been 
synthesised successfully. This section of the chapter will concentrate on giving an 
overview of the various approaches that have been used in the synthesis of both linear and 
cyclic diarylheptanoids.  
 
2.5.1 Synthesis of linear diarylheptanoids 
 
2.5.1.1 Biosynthesis of linear diarylheptanoids 
 
The biosynthesis of curcumoids has been investigated owing to their importance to human 
health and nutrition. The initial investigation of the biosynthesis of curcumoids was carried 
out by Whiting et al.22 They proposed two mechanistic pathways by which curcumoids are 
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Scheme 2.1. Biosynthesis of linear diarylheptanoids 
 
Enough experimental evidence has not been obtained to confirm either of the pathways. 
However, studies with different plant species have indicated that both pathway a and b 
may operate in the biosynthesis of diarylheptanoids7. 
 
2.5.1.2 Synthesis of linear diarylheptanoids 
 
Linear diarylheptanoids have relatively simple structures and thus easily accessible using 
today’s synthetic methodologies. Linear diarylheptanoids differ by the substituents on the 
phenyl rings and by the oxygen functional groups such as OH and C=O on the 
seven-carbon aliphatic chain. In addition to this, diarylheptanoids with both unsaturated 
and saturated aliphatic chains have been isolated. Thus a general strategy for the synthesis 
of linear diarylheptanoids should allow ready variation of the substituents on the phenyl 
rings and incorporation of various oxygen functional groups on the aliphatic chain. The 
synthesis of linear diarylheptanoids can be classified according to the ways in which the 
seven carbon aliphatic chain could be assembled; C1-moiety + C6-moiety strategy, 
C2-moiety + C5-moiety strategy, C3-moiety + C4-moiety strategy, C1-moiety + C5-moiety + 
C1-moiety strategy. 
 
2.5.1.2.1 C1-Moiety + C6-moiety 
 
Gonzalez and Zhu used the C6-moiety + C1-moiety strategy to synthesis the 





transformations to afford the desired diarylheptanoid (Scheme 2.4).  The key steps of the 
reaction is the chain elongation to form the C6-moiety which was obtained by the double 
deprotonation of methyl acetoacetate using LDA followed by addition of the iodide 40, 
The C1-moiety was synthesised using the Finkelstein reaction, in which the bromide group 
of 4-fluoro-3-nitrobenzyl bromide was replaced by an iodide group to form 42. The two 
precursors were then combined by nucleophilic substitution of the C1-moity (42) to the 
C6-moiety (41) to form the seven carbon aliphatic chain. This was followed by the 
chemoselective removal of the isopropyl protecting group followed by decarboxylation to 











































Scheme 2.2. Reagents and yields: (a) iPrBr, K2CO3, 96%, (b) LiAlH4, 97%, (c) TsCl, Py, 87% (d) 
NaI, 80%, (e) methyl acetoacetate, LDA, 80% (f) NaH, 76% (g) BCl3 (h) 6N HCl, 93% 
 
Itokawa et al.24 also used the C1-moiety + C6 moiety for the synthesis of yakuchinone-A 
(46) and B (47), linear diarylheptanoids isolated from Alpinia oxyphylla. Scheme 2.5 
outlines the major step in the synthesis of 46 and 47. They utilized the Claisen-Schmidt 
reaction for the condensation of vanillin (44) (C1-moiety) with 6-phenyl-2-hexanone (45) 




















(44) (45) (46) (47)
 
Scheme 2.3. Synthesis of yakuchinone-A and -B 
 
2.5.1.2.2 C2-Moiety + C5-moiety strategy 
 
Narasimhulu et al.25 synthesized the diarylheptanoid yashabushidiol (52), isolated from the 
male flowers of Alnus sieboldiana. The readily available starting material D-mannitol 
diacetonide was used as the starting material for the synthesis of the C5-moiety (48), 
whereas vanillin was used as the starting material for the C2-moiety (49). The key step of 
the synthesis was the alkenylation reaction in which the C2-moiety adds to the C5-moiety 
via nucleophilic addition. Scheme 2.6 outlines the synthetic procedure used for the 
coupling of the C2 and C5-moiety to obtain the seven-carbon aliphatic chain. The reaction 
proceeded in 90% yield to afford a mixture of two diastereomers (51) in a ratio 40:60 














(51) (52)  
Scheme 2.4. Reagents and yields: (a) n-BuLi, 90%; (b) 10% Pd/C, 95% (c) PTSA, MeOH, rt, 1 h, 
95% 
 
2.5.1.2.3 C3-Moiety + C4-moiety strategy 
 
Henly-Smith et al.3  reported the synthesis of a linear diarylheptanoid using a C3-moiety + 





reaction (Route 1) and a reaction based on dithiane chemistry (Route 2) to couple the two 
moieties.  Scheme 2.5 outlines the synthetic route used by Henly-Smith et al.3 to assemble 
the seven-carbon aliphatic chain. The assembly of the two moieties using Grignard 
reaction between 53 and 54 gave only a 48% yield of 55, whereas the dithiane route in 




























Scheme 2.5. Synthesis of a diarylheptanoid using the Grignard reaction route and dithiane route. 
 
2.5.1.2.4 C1-Moiety + C5-moiety + C1-moiety strategy 
 
Venkateswarlu et al.26 devised an efficient and short synthetic strategy for the synthesis of 
curcumin analogues using the aldol condensation. The main steps in the synthetic route, as 
shown in Scheme 2.8,  was the protection of carbonyl group of acetylacetone (C5-moiety) 
(60) with boric oxide to form an acetylacetone-boric oxide complex (61), which was then 
reacted with substituted benzaldehydes (C1-moiety) and finally the boron complex of the 
product was decomposed using aqueous acetic acid to get the desired curcumin analogs 
(62)26. The C-3 of 2,4-pentadione bears more acidic protons than C-1/C-5 and thus 
Knoevenagel condensation at C-3 competes with the aldol condensation on the terminal 
methyl groups. However, boron-based protecting groups reduce the nucleophilicity of the 



























Scheme 2.6. Synthesis of diarylheptanoids using boron based protecting groups 
 
Later on, Lee et al.13 used the same strategy to synthesise heterocycles containing 
curcumin analogues and symmetric and asymmetric curcumin analogues with different 























Synthetic method for monophneyl curcumin analogues
Synthetic method of symmetric curumin analogues








Scheme 2.7.General synthetic routes for the synthesis of curcumin analogues 
 
Nichols et al.27 performed the same reaction described above for the synthesis of curcumin 
analogues using microwave energy (Scheme 2.8).  The procedure adopted by them allowed 
the synthesis of the desired analogues in a short time period compared to the heating under 

















n = 0,1  
Scheme 2.8. Synthesis of diarylheptanoids using boron-based protecting groups under microwave 
irradiation 
 
2.5.2 Synthesis of cyclic diarylheptanoids 
 
The total synthesis of cyclic diarylheptanoids has interested chemists for decades owing to 
their biological activities.  Thus various synthetic methods have been developed for the 
synthesis of cyclic diarylheptanoids such as intramolecular ring-closure metathesis, 
intramolecular Wittig reactions, intramolecular oxidative coupling, intramolecular 
nucleophilic aromatic substitution reaction (SNAr) and transition metal-catalyzed 
reactions7. Synthesis of cyclic diarylheptanoids involves the formation of carbon-carbon 
bonds at the aliphatic chains or macrocyclisation via formation of an aryl-aryl or an 
aryl-aryl ether bond. This section will review the various synthetic strategies that have 
been used for the synthesis of the cyclic diarylheptanoids. 
 
2.5.2.1 Biosynthesis of cyclic diarylheptanoids 
 
Cyclic diarylheptanoids have been found in co-occurrence with their corresponding linear 
diarylheptanoids in plants such as A. japonica and A. nikoense. Thus intramolecular 
phenolic oxidative coupling have been the biosynthetic route proposed for cyclic 
diarylheptanoids. Scheme 2.11 outlines the proposed biosynthetic route. The linear 


















Scheme 2.9. Biosynthesis of cyclic diarylheptanoids 
 
 
2.5.2.2 meta,meta-Bridged biphenyls 
 
Semmelhack et al.28 investigated the zerovalent nickel promoted aryl-aryl bond formation. 
From their study it was found that tetrakis(triphenylphosphine)nickel gave the desired 
aryl-aryl coupling in good yield. According to Semmelhack et al.28, the reaction proceeds 
via oxidative addition of the organic halide to Ni(0). However, this cyclisation technique 
does not yield good results with sterically hindered ortho-disubstituted substrates 
(Scheme 2.10). Even so, this methodology is a good alternative to the traditional Ullmann 
reaction, which requires drastic conditions thus making it less efficient for the construction 











n = 1, yield 81%
n = 4, yield 85%
n = 5, yield 38%
 






Semmelhack and co-workers, utilised the method which they developed, for the synthesis 
of alnusone (65), a m,m-bridged biphenyl (Scheme 2.11). The cyclisation of 64 using 












Scheme 2.11. Zerovalent nickel promoted synthesis of m,m-bridged biphenyl diarylheptanoid 
 
Whiting et al.22 investigated the aryl-aryl cyclisation of appropriate 1,7-diarylheptanoids to 
form  m,m-bridged biphenyl diarylheptanoids. In their study, different coupling strategies 
were used namely, oxidative coupling, photochemical radical coupling and Ni0 catalysed 
coupling22. Scheme 2.12 summarises the results obtained in this study. The oxidative 
coupling of 66 using thallium(III) tristrifluoroacetate yielded the C-O coupling to form 
m,p-bridged biphenyl (67), but both photochemical radical coupling and Ni0 catalysed 





























Scheme 2.12. Cyclisation to form ,m-bridged biphenyls using different strategies 
 
2.5.2.3 meta,para-Bridged biphenyls 
 
Keseru and co-workers developed a synthetic scheme for the synthesis of garuganin III 
(71), a macrocylic diarylheptanoid isolated from the Indian medicinal plant Garuga 
pinnata4. The key steps for the synthesis followed by them are; (i) preparation of an 
unsymetrically substituted diphenyl ether (69) (ii) addition of a C5 unit to the diphenyl 
ether as an isoxazol, which also served as a masked 1,3-dicarbonyl synthon to form 70 (iii) 
ring closure using an intramolecular Wittig reaction and lastly transformation of the 
isoxazole into the desired β-methoxy enone 714. The synthetic route followed by Keseru 
















































Scheme 2.13. Synthesis of garuganin III (71) 
 
In another report, Vermes et al. used a similar strategy to synthesise garugamblin-1, a 
variant of garuganin III (73) but the ring closure was accomplished by the 
Wurtz-Boekelheide method29.  In this method, the intermediate (70) is treated with a 
radical anion generated from sodium and tetraphenylethene29. 
Gonzalez and Zhu utilised the intramolecular SNAr reaction for the synthesis of the aryl 
ether bond of the m,p-bridged diarylheptanoid, acerogenin A (74)2.  The synthesis was 
carried out by firstly preparing the corresponding linear diarylheptanoid 72 which was then 
subjected cylcoetherification. Scheme 2.14 outlines the synthetic route starting from the 
linear diarylheptanoid. The cyclisation occurred smoothly to give the macrocylce 73 in 
quantitative yield2. Gonzalez and Zhu reported that even at high concentrations of the 
linear diarylheptanoid, the cyclic product was obtained in quantitative yield. This provides 
evidence that the intramolecular reaction of the linear diarylheptanoid is highly 














0.01 M       90-95%
0.05 M       90-95%
0.1 M       75-80%








Scheme 2.14. Synthesis of acerogenin A (77) 
 
2.5.2.4 Tetrahydropyran-type cyclic diarylheptanoids 
 
One of the most commonly used reaction for the formation of tetrahydropyran-type 
diarylheptanoids is the Prins reaction. Hiebel et al.15 used Prins cyclisation for the 
synthesis of diospongin A(77), which has a 2,4,6-trisubstituted tetrahydropyran ring as the 
core. The key step of the synthesis was the acid-mediated Prins reaction between the 
homoallylic alcohol (76) and benzaldehyde (75) to form the tetrahydropyran ring, which 
was then subjected to the Mitsunobu reaction in order to get the desired stereochemistry 















(i) PPh3, DEAD, p-nitrobenzoic acid
(ii) NaOH, MeOH, THF, H2O
TFA, rt
 
Scheme 2.15. Synthesis of (±)-diospongin A (77) 
 
Parker et al.30 also used Prins cyclisation as the key step for the synthesis of the calyxin-
type natural product, 4-acetoxy-2,6-disubstituted tetrahydropyrans (80), isolated from 
Zingiber officinale. The Prins cyclisation between the homoallylic alcohol (78) and the 




















(i) BF3.OEt2, TMSOAc, AcOH
(ii) K 2CO3,MeOH
 
Scheme 2.16. Synthesis of 4-acetoxy-2,6-disubstituted tetrahydropyrans 
 
Tian et al.9 used a tandem Prins cyclisation a d a Friedel-Crafts reactions with an 
electron-rich aromatic ring to synthesise the core structures of a calyxin natural product 
(Scheme 2.17). Even though the Prins cyclisation normally leads to a tetrahydropyran 
rings with a heteroatom at the C-4 position, Tian  et al. reported that under certain 
circumstances the electrophilic C-4 position reacts with an aromatic ring in a Friedel-
Crafts alkylation reaction, introducing an aryl group in the equatorial position9. As a result, 
this reaction enables the introduction of structural complexity thus making it a useful 
synthetic method. The carbon skeleton of epicalyxin F (86) was assembled in a single step 
by the Prins cyclisation and Friedel-Crafts trapping of the ester of alcohol 82 with acid 81 
to form the acetoxy ether 83. Precursor 83 was then subjected to another Prins cyclisation 
to form the core unit of epicalyxin F (84). This was followed by the lithiation of the aryl 
bromide (85) and addition of the unsaturated aldehyde leading to the formation of 


















































In summary, diarylheptanoids are an important class of plant secondary metabolites 
exhibiting a broad range of biological activities.  Diarylheptanoids have mostly been 
isolated from plants of Zingiberacea family. Diarylheptanoids that have been isolated from 
various plant species vary significantly in their structure. Owing to their significant 
biological activities, the total synthesis of natural diarylheptanoids and their analogues 
have been investigated. Thus total synthesis of many of the diarylheptanoids has been 
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The aim of this investigation was to synthesise a novel diarylheptanoid (17) isolated from 
the South African medicinal plant Siphonochilus aethiopicus. As outlined in Chapter 2, 
diarylheptanoids are a class of plant metabolites exhibiting a variety of biological 
activities.  The total synthesis of compound 17 would enable the evaluation of its 
biological activities and also would provide a means for synthesising analogues of this 
compound. In the literature, various synthetic methodologies have been published for the 
synthesis of diarylheptanoids, which have been briefly explained in Chapter 2. This 
Chapter will describe the work that has been done towards the total synthesis of compound 
17 during this research. 
 
3.2 Retrosynthetic Analysis 
 
The targeted diarylheptanoid (17) contains two electron-rich aromatic rings connected by a 
seven-carbon aliphatic chain containing a tr ns-alkene functional group and two 
stereogenic centres at positions 5 and 6, respectively.  The intended synthetic strategy is 
the C2-moiety + C5-moiety strategy. Thus the molecule was disconnected at the double 
bond at the C-2 positions of the aliphatic chain, leading to two major precursors. 























































Scheme 3.1. Retrosynthetic analysis of the novel diarylheptanoid 
 
Rout 1 (Scheme 3.1), was the chosen synthetic pathway for the synthesis of compound 17. 
The alternative route (Route 2) for the synthesis of the compound 17 with starting material 
87a and 88a, outlined in Scheme 3.1, was also considered. However, owing to the 
instability of the aldehyde under basic conditions, this route is not feasible for the total 
synthesis of compound 17. The instability of aldehyds of the type 87a could be attributed 
to the acidic protons which would be deprotonated under mild basic conditions thus 
leading to self condensation.  
The synthesis of the target compound was based on three major sections; synthesis of 
C2-moiety (87), synthesis of C5-moiety (88) and the coupling of the two moieties to form 
the required diarylheptanoid. Simple functional group conversions will be utilised for the 
synthesis of both the precursors and Wittig-type olefination reactions will be used for the 
formation of the trans-double bond eventually leading to the required diarylheptanoid. 
 
3.3 Preliminary Investigation 
 
A preliminary investigation was carried out in order to evaluate different Wittig reactions 





Wittig reactions are very useful for generating double bonds, usually with high geometrical 
control. Owing to its wide use in synthetic chemistry, we decided to utilise a Wittig-type 
reaction for the construction of the E-alkene.  Consideration of the mechanistic details of 
the reaction has revealed ways of controlling the stereoselectivity of the Wittig reaction1. 
Scheme 3.2 outlines the general mechanistic pathway for the Wittig reaction. This reaction 
proceeds in three steps: addition of the phosphorane to an aldehyde forming an 
intermediate betaine (89), followed by the formation of the phosphorous-oxygen bond and 
finally collapse of the oxophosphetane intermediate by syn-elimination to form the cis or 
trans olefin.  The stereoselectivity of the Wittig reaction is dependent on the type of ylide 
and on the substituents bonded to the phosphorus atom. Non-stabilised ylides favour 



















































































Scheme 3.2. General mechanistic pathway for Wittig reaction 
 
Over the past decade various modifications of the Wittig reaction has been introduced. 
These include the Wittig-Schlosser3 reaction and the Horner-Wadsworth-Emmons reaction 
for E-selective olefination. We decided to investigate these two modifications of the Wittig 








3.3.1 Wittig-Schlosser reaction 
 
The Schlosser modification of the Wittig reaction allows the selective formation of the 
E-alkenes1. In this variant of the Wittig reaction, excess lithium adduct is used in the 
addition of the ylide and in the subsequent deprotonation step3.When excess lithium adduct 
is added, the erythro-betaine intermediate (90) which leads to the formation of the 





















































Scheme 3.3. The Schlosser modification of the Wittig reaction 
 
To investigate the stereoselectivity of the Wittig-Schlosser reaction, we designed a model 

















The synthesis of compound 93 began with the formation of the phosphorous ylide 92 as 
shown in Scheme 3.5. Compound 92 was synthesized in 99% yield by refluxing a mixture 
of 2-phenylethyl bromide and triphenylphosphine in toluene. Formation of compound 92 
was confirmed by 1H NMR and 13C NMR spectroscopy.  The 13C NMR spectrum of this 


















Scheme 3.5. Synthesis of compound 93 
 
Having synthesised the Wittig ylide (92), we attempted the Wittig-Schlosser reaction. The 
reaction was carried out by firstly stirring the base with the Wittig ylide at room 
temperature for one hour. This was then followed by another addition of the base to 
facilitate the inter-conversion of the erythro betaine to the threo betaine. The aldehyde was 
then added to the reaction mixture. The required product, 93, was obtained in 70% yield as 
mixture of both the cis- and trans- isomers. 1H NMR spectroscopy of compound 93 was 
used to determine the stereoselectivity of the reaction. The 1H NMR spectrum (Plate 3a), 
showed peaks corresponding to both the E- and the Z-isomers, with the Z-isomer as the 
major product of the reaction (Z:E, 8:2). The peaks which correspond to the Z-isomer are a 
doublet at δH 3.72 (Ar-CH2-CH=CH), doublet of triplet at δH 5.91 (Ar-CH2-CH=CH) and 
the doublet at δH 6.63 (Ar-CH2-CH=CH) with an olefinic coupling constant of 11.6 Hz, 
characteristic of that of a Z-alkene. The 1H NMR peaks which corresponds to the E-alkene 
are further upfield compared to that of the Z-alkene; a doublet at δH 3.59 (Ar-CH2-
CH=CH), a doublet of triplets at 6.40 (Ar-CH2-CH=CH) and a doublet at δH 6.50 
(Ar-CH2-CH=CH) with a olefinic coupling constant of 15.8 Hz, characteristic of a E-
alkene.   
 Having failed to obtain the E-isomer exclusively, we attempted to increase the E:Z ratio 
by changing the reaction conditions. The reaction was initially started at -70 °C and 
allowed to warm to 0 °C. We increased the temperature to 0 °C-25 °C, but isolated only 





this also failed to bring about any significant change in the E:Z ratio.                  
Changes in reaction temperature had little effect upon the product ratio. Since the 
Wittig-Schlosser reaction did not yield the E-isomer exclusively, it cannot be used in the 
total synthesis of the targeted diarylheptanoid.  
3.3.2 Horner-Wadsworth-Emmons Reaction 
 
The phosphonate modification of the Wittig reaction is known as the Horner-Wadsworth-
Emmons (HWE) reaction. The HWE reaction uses a resonance-stabilised phosphonate 
carbanion which undergoes reaction with carbonyl compounds2. The HWE reaction is 
advantageous over the conventional Wittig reaction since the phosphonate carbanions are 
more nucleophilic than the phosphonium ylides and thus react with a wider variety of 
aldehydes and ketones under milder conditions2.  In contrast to the conventional Wittig 
reaction, HWE reaction has a two-step mechanism (Scheme 3.6).  In the first step, the 
carbanion reacts with the carbonyl compound to form an intermediate oxyanion (94)3.  In 
the second step, the intermediate decomposes by oxygen transfer to the phosphorous atom 

















































Scheme 3.6. Mechanism for the HWE reaction 
 
The stereochemistry of the HWE reaction generally favors the formation of the E-alkene, 
thus the formation and the decomposition of the thr o betaine (96) would be much faster 
than that of the erythro betaine (95)2, 4 (Scheme 3.7). This outcome could be explained by 
considering the steric effects of the two betaine intermediates. The erythro betain (95) is 
much more sterically hindered than the threo betaine (96) in the eclipse conformation 
required for the syn elimination. Thus the erythro betaine (95), which will lead to the 
Z-alkene, will be formed at a slower rate than the thr o betaine (96)2, 4. However, methods 



















































Scheme 3.7. Mechanism for the HWE reaction 
 
To investigate the stereoselectivity of the HWE reaction, we designed a model reaction 
similar to that shown in Scheme 3.5. Scheme 3.8 outlines the synthesis of a model 
















Scheme 3.8. Synthesis of 93 using the HWE reaction 
 
The first step was the synthesis of the phosphonate (97) by refluxing a mixture of 
2-phenylethyl bromide and triethyl phosphite. Compound 97 was obtained as a yellow oil 
in an excellent yield of 98%. The formation of phosphonate 97 was confirmed by 1H NMR 
and 13C NMR spectra. The 1H NMR spectrum of compound 97 showed a triplet at δH 1.30 
and a quartet at δH 4.15 corresponding to the ethyl group of the phosphonate ester (Plate 





Ph-CH2CH2P had the largest coupling constant of 139.7 Hz. Both 
1J and 2J coupling were 
seen on the 13C NMR spectrum of the phosphonate ester (Plate 2b). 
Having compound 97 in hand, we attempted the HWE reaction using benzaldehyde as 
shown in Scheme 3.8. The required E-isomer was obtained in this reaction in 41% yield. 
The 1H NMR spectrum of the product showed that the major product of the reaction was 
the E-isomer (Plate 4a) with a minute quantity of theZ-isomer present. Thus we decided to 
use the HWE reaction to couple the two moieties, 87 and 88, in order to form the targeted 
olefin. 
 
3.4 Synthesis of Precursors 
 
3.4.1 Synthesis of C2-moiety 
 
The C2-moiety is the diethyl phosphonate for the HWE reaction. Scheme 3.9 outlines the 
retrosynthetic analysis of compound 87.  As outlined in this Scheme 3.9,  the synthesis of 
compound 87 is based on simple functional group conversion thus making it a convenient 
synthesis.  The starting material for the synthesis of compound 87 was gallic acid (98), 
which has a m-hydroxylated aromatic ring, consistent with the substitution pattern of the 
aromatic ring of compound 87. Selective protection of the two adjacent hydroxy groups of 













































Scheme 3.10 outlines the strategy for the synthesis of compound 87. The first step of the 
synthesis was the esterification of the carboxylic acid group of gallic acid (98) to form 
methyl gallate (99). This reaction was carried out under acidic conditions to form the 
required compound in an excellent yield of 97%. Formation of compound 99 was 
confirmed by 1H NMR which showed a distinguishing singlet for the methoxy group at δH





























































































Scheme 3.10. Synthetic route for 87
 
The second step of the synthesis was the regioselective protection of two adjacent hydroxy 
groups of 99 as an acetal using ethyl orthoformate. The orthoformate protecting was 
performed under acid-catalysed conditions. Since 99 is a symmetrical molecule, this 
reaction is chemoselective thus leading to the formation of one compound even though 





form compound 100. Both benzene and toluene were used as solvents for this reaction. It 
was found that when using toluene as the solvent, the reaction time decreased significantly.  
This decrease in reaction time could be attributed to higher reaction temperature when 
refluxed in toluene. The boiling point to toluene is 110 °C whereas the boiling point of 
benzene is 80 °C. Formation of compound 100 was confirmed by 1H NMR spectroscopy. 
The 1H NMR spectrum showed a triplet at δH 1.17 and a quartet at δH 3.70, corresponding 
to the ethyl orthoformate group of compound 100 (Plate 6a). 
The next step of the synthesis was the protection of the remaining hydroxy group. Since 
the protecting group needs to be kept intact throughout the synthesis, a less sensitive 
protecting group had to be chosen. Thus the free hydroxy group was protected as a 
benzyl ether. This reaction proceeds in 79% yield to form the required compound 101. The 
1H NMR spectrum of compound 101 had a singlet at δH 5.24 and a multiplet at δH 
7.36-7.50, which corresponded to the benzyl group. 
Having compound 101 in hand, the deprotection of the acetal protecting group to form 102 
was achieved by stirring acetal 101 in MeOH under acidic conditions. The 1H NMR 
spectrum of 102 did not have the peaks corresponding to the ethyl orthoformate protecting 
group, which were at δH 1.17 and δH 3.10 in the 
1H NMR spectrum of 101 (Plate 7a). 
The subsequent methylation of the two phenolic groups at C-4 and C-5 of the phenyl ring 
furnished compound 103 in an excellent yield of 95%.  The three singlets at δH 3.91, 3.92 
and 3.94, each integrating for three protons in the 1H NMR spectrum (Plate 8a) of 
compound 103, correspond to the three methoxy groups in 103. With the successful 
synthesis of ester 103, we have managed to obtain the required substitution of the phenyl 
ring, which is consistent with the substitution on the phenyl ring of compound 87. 
The next step was to synthesise the required two-carbon aliphatic chain. In order to 
accomplish this, the ester group of 103 was first reduced to the alcohol using LiAlH4 to 
form alcohol 104. This reaction gave a good yield of 84%. The 1H NMR spectrum of 104 
had three singlets at δH 3.84, 3.87 (corresponding to two methoxy groups) and δH 4.56 
(corresponding to CH2OH) (Plate 9a). Furthermore, due to the increase in electron density 
on the phenyl ring because of the removal of the electron-withdrawing ester group, the 
signals corresponding to the phenyl protons in the 1H NMR spectrum moved upfield. For 
compound 103, the signals for the two phenyl protons are very close to the benzyl proton 





compound 104 (Plate 9a), the signals for the two phenyl protons appeared separately from 
the benzyl protons at δH 6.59  and δH 6.63.  
Following the successful synthesis of the alcohol, it was oxidised to the aldehyde using 
2-iodoxybenzoic acid. 2-Iodoxybenzoic acid is an organic compound used in organic 
synthesis as an oxidizing agent. It is especially suited to oxidize alcohols to aldehydes. 
IBX is prepared from 2-iodobenzoic acid, potassium bromate and sulfuric acid7. This 
reaction proceeded in 96% yield to afford the required compound 105.  The formation of 
aldehyde 105 was confirmed by the 1H NMR spectrum, which had the diagnostic aldehyde 
proton peak at δH 9.84 and the 
13C NMR spectrum also showed the carbonyl carbon peak 
at δC 190.9 (Plate 11a and 11b).  Furthermore, the 
1H NMR and 13C NMR peaks for 105 
moved downfield as compared to the peaks of 104. This is due to the replacement of the 
hydroxy group of 105 with an electron-withdrawing carbonyl group thus decreasing the 
electron density of the phenyl ring. 
The subsequent Wittig olefination of aldehyde 105 with methyltriphenylphosphonium 
iodide furnished styrene 106 in 70% yield. The 1H NMR spectrum of 106 showed the 
peaks corresponding to the CH=CH2 group protons; a doublet at δH 5.63 with a coupling 
constant of 17.5 Hz corresponding to the rans terminal proton on the CH=CH2 group and 
the doublet of doublets at δH 6.62 with a coupling constant of 17.5 Hz for CH=CH2 proton 
(Plate 12a). The doublet of doublets seen for CH= H2, indicates that the terminal two 
protons are non-identical, even though they are bonded to the same sp2 carbon.  The peak 
intensities of the signal for CH=CH2 proton was 1:1:1:1, thus confirming that it is a 
doublet of doublets. 
The next step of the synthesis was the hydroboration-oxidation of the alkene 106 to form 
the alcohol 107.  This is a two-step reaction in which hydroboration is accomplished by the 
addition of a boron hydride to the C=C bond as shown in Scheme 3.11.  
 
+ R2B H H BR2
alkene Boron hydride organoborane
 






Following hydroboration, the organoborane is oxidised using hydrogen peroxide in 
aqueous base thus converting the organoborane to an alcohol (Scheme 3.12).  
 




Scheme 3.12. Hydroboration-oxidation 
 
Hydroboration-oxidation was chosen for this step because it leads to the anti-Markovnikov 
product, whereas acid-catalysed conversion of alkenes to alcohols will lead to the 
Markovnikov product. This difference in regioselectivity could be attributed to steric 
effects; boron has a tendency to become bonded to the less substituted carbon of the 
double bond thus leading to the anti-Markovnikov product. The hydroboration-oxidation 
of 106 yielded 107 as the major product (55% yield) and Markovnikov product (15% 
yield) as the minor product. The formation of 107 was confirmed by 1H NMR which 
showed two triplets at δH 2.78 and 3.81, corresponding to CH2CH2OH signals (Plate 13a). 
Having the required alcohol 107 in hand, the next step was the conversion of the alcohol 
107 to the alkyl halide 108, which could then be converted into the phosphonate ester (87). 
This was done by bromination of the alcohol group using PBr3 to form bromide 108 in 
60% yield. The triplets corresponding to the CH2 2Br, in the 
1H NMR spectrum of 
compound 108 shifted downfield compared to that of alcohol 107 because of the 
introduction of a more electronegative bromide group (Plate 14a).  
The last step is the synthesis of the C2-moiety was the preparation of the phosphonate ester 
87. Compound 87 was synthesised by refluxing 107 with triethyl phosphite. The reaction 
proceeded in 73% yield to give the required compound 87. 1H NMR and 13C NMR 
spectroscopy were used to confirm the formation of 87. The 1H NMR spectrum of 
compound 87 had a triplet at δH 1.34 and a quartet at δH 4.11, corresponding to the diethyl 
phosphonate group of 87 (Plate 15a). The 13C NMR spectrum of 87 showed significant 
13C-31P coupling. A coupling constant of 139.2 Hz was seen for the 1J coupling, 4.4 Hz for 
2J coupling and 17.4 Hz for 3J coupling of carbon-13 to phosphorous-31 (Plate 15b). The 
coupling constants that were obtained are in agreement with those from the literature. The 





and co-workers were in close agreement with the J values we obtained8. Takahashi et al. 
reported 140.3 Hz for 1J coupling, 4.4 Hz for 2J coupling and 17.4 Hz for 3J coupling8.  
Furthermore, the 31P NMR spectrum of compound 87 showed a sharp peak at δP 30.56, 
indicating the presence of a phosphorous atom in the compound. 
3.4.2 Synthesis of C5-moiety 
 
Structural analysis of the C5-moiety shows an electron-rich aromatic ring and a five-carbon 
aliphatic chain with two stereogenic centres. Scheme 3.13 outlines the retrosynthetic 
analysis for the synthesis of 88. Based on the retrosynthetic analysis outlined in Scheme 
3.13, a synthetic strategy was developed and is shown in Scheme 3.14. The starting 
material chosen for the synthesis of 88 was vanillin (109) which has substituents on the 
meta and para positions of the aromatic ring, consistent with the substituents on the 
aromatic ring of the C5-moiety. The first step of the synthesis would be the protection of 
the para-hydroxy group of vanillin as a benzyl ether. This would be the right choice of 
protecting group since 87 also contains a benzyl ether protecting group. Furthermore, the 
protecting group of the p-OH group is kept all throughout the synthesis, thus a fairly stable 
protecting group such as a benzyl ether group is appropriate. The second step of the 
synthesis would be the HWE reaction which would then be followed by the sequential 
reductions of the C=C bond and the ester group. The resulting hydroxy would then be 
oxidised to an aldehyde and reacted with malonic acid to form the required five carbon 
aliphatic chain with a C=C double bond between C-3 and C-4 position.  The next step 
would be the Sharpless asymmetric dihydroxyation of the C=C bond. In order to achieve 
the required stereochemistry, AD-mix, which is a mixture of reagents containing a chiral 












































Scheme 3.13. Retrosynthesis for C5-moiety 
 
The benzylation of the commercially available vanillin (109) was performed using benzyl 
chloride in the presence of K2CO3 (Scheme 3.14). This reaction proceeded in 85% yield to 
give 110. The diagnostic peaks of the benzyl ether were seen on the 1H NMR spectrum of 
110, a singlet corresponding to the O-CH2 protons at δH 5.26 and a multiplet corresponding 
to the benzyl protons at δH 7.31-7.47 (Plate 16a). 
This was followed by the HWE reaction of compound 110 with triethyl phosphonoacetate 
using NaH as a base, to form the α,β-unsaturated ester 111. This reaction proceeded in an 
excellent yield of 97%. The successful synthesis of 111 was confirmed by 1H NMR 
spectroscopy. The spectrum (Plate 17a) showed two doublets at δH 6.32 and δH 7.63 with a 
coupling constant of 15.9 Hz, corresponding to the two rans-olefinic protons on the 
aliphatic chain of 111. 
The subsequent reduction of the C=C bond using H2 in the presence of 10% Pd/C catalyst, 
led to the formation of compound 112. This reaction had to be done under careful time 
control because elongated reaction times cause reduction of not only the double bonds, but 
also lead to debenzylation. The optimum time was found to be 15 min for 2 g of compound 
111. The successful reduction of the C=C bond was corroborated by the 1H NMR spectrum 
which showed two triplets at δH 2.61 and 2.91, corresponding to the CH2 H2 protons of 





Compound 112 was then successfully reduced to the corresponding alcohol (113). The 
reducing agent used was LiAlH4 and the reaction proceeded in an excellent yield of 89% to 
form alcohol 113. The 1H NMR spectrum (Plate 19a) for 113 confirmed the success of the 
reaction; the quintet at δH 1.89 corresponding to the CH2CH2CH2OH protons is diagnostic 
for compound 113. Furthermore, the peaks corresponding to the aliphatic protons moved 
downfield compared to that of the aliphatic proton peaks of 112 due to the absence of the 








































































Scheme 3.14. Synthetic route for the C5-moiety 
 
The alcohol 113 was then oxidised to form the subsequent aldehyde (114). The oxidising 
agent used for this step was 2-iodoxybenzoic acid and the reaction proceeded in a good 
yield of 79%. The 1H NMR spectrum of compound 114 had the characteristic aldehyde 






of 113 was not present in the 1H NMR of compound 114; instead two triplets at δH 2.77 
and δH 2.92, corresponding to the aliphatic protons were seen. 
Having successfully synthesised the aldehyde, the next step of the synthesis was the 
Knoevenagel condensation of aldehyde 114 with malonic acid to form the β,γ-unsaturated 
acid 115. The formation of the β,γ-unsaturated acid 115 was confirmed by using 1H NMR 
and 13C NMR. The 1H NMR spectrum of compound 115 showed two doublets at δH 3.14 
and δH 3.34, which correspond to the two pairs of CH2-protons on the aliphatic chain. 
Furthermore, a multiplet was present in the 1H NMR spectrum between δH 5.68-5.59, 
corresponding to the two CH=CH-protons (Plate 21a). Although it has been reported by 
Kumar et al. that the major product of this type for condensation is the α,β-unsaturated 
acid9, we obtained the β,γ-unsaturated acid as our sole product in excellent yield of 99%.  
The Knoevenagel condensation using malonic acid has been reported to yield both the α,β- 
and β,γ-unsaturated acids but affords the highest yield of the β,γ-unsaturated acid10. Duarte 
et al. reported the formation of the α,β-unsaturated acid in 94-95% yield using the reagents 












Scheme 3.15. Knoevenagel condensation 
 
 We also utilised the same reagents, but under microwave irradiation, to obtain solely the 
β,γ-unsaturated acid. It is also worth noting that we obtained the β,γ-unsaturated acid, even 
under reflux using the same reagents, but in a much lower yield of 45%. The results 
obtained for the Knoevenagel condensation are in agreement with the results obtained by 
Sabitha et al.12. Sabitha et al.12 used a modified Knoevenagel condensation method which 
utilises SiO2 as a catalyst under microwave irradiation, described by Kumar et al.
9, to form 
the β,γ-unsaturated acid in 60% yield. Scheme 3.17 shows the proposed mechanism for the 















































Scheme 3.16. Mechanism for Knoevenagel condensation 
There are three steps in the proposed mechanism: addition of the enolate to the aldehyde, 
decarboxylation and double bond rearrangement. In the addition step, an enolate ion is 
formed which then attacks the aldehyde. This step is followed by decarboxylation leading 
to the E-alkene. In the next step the double bond moves from the conjugated α,β-position 
to the non-conjugated β,γ-position. According to E.J. Corey, the formation of the 






















α,β-unsaturated acid γ,β-unsaturated acid 
Scheme 3.17. Mechanism for the formation of β,γ-unsaturated acid isomer in Knoevenagel 
condensation 
 
Having made the β,γ-unsaturated acid (115), it was converted into the corresponding ester, 
116. The treatment of acid, 115 with BF3.OEt2 in methanol under standard conditions lead 
to the compound 116. The 1H NMR was used to confirm the formation of the product 
which had two singlets each integrating to three at δH 3.71 and 3.90 corresponding to the 
two methoxy groups (Plate 22a).  
This was then followed by the reduction of the ester group to the corresponding alcohol 





be followed by the asymmetric dihydroxyation of the double bonds. If the dihydroxyation 
was carried out on 116, the corresponding lactone would result. Sabitha et l.12 formed the 
lactone (121) by the dihydroxyation of 120, which is similar in structure to compound 116 













Scheme 3.18. Asymmetric dihydroxylation 
 
The 1H NMR spectrum (Plate 23a) of compound 117 had a quartet at δH 2.32 and a triplet 
at δH 3.67 which distinguishes it from the 
1H NMR spectrum (Plate 22a) of compound 116. 
As expected, the singlet corresponding to the COOCH3 group, on the 
1H NMR spectrum of 
116 was not seen on the 1H NMR spectrum of compound 117.  
Having the required alcohol in hand, we attempted to oxidize the alcohol (117) to the 
subsequent aldehyde (118) using 2-iodoxybenzoic acid. However, we were not able to 
obtain the required aldehyde 118 as the sole product of the reaction, instead a mixture of 
products was isolated. Scheme 3.19 outlines the products obtained in this reaction. The 
plausible explanation for this outcome is the movement of the double bond to form the 
more stable conjugated systems. The carbon-carbon double bond of compound 118 is not 
conjugated to either the phenyl group or the carbonyl group but in compound 122 and 123 
the double bond is conjugated to the phenyl group and the carbonyl group respectively, 
thus making them more stable. Under acidic conditions, carbon carbon double bonds have 
a tendency to migrate to a more conjugated position. The acidity of this reaction can be 
attributed to the oxidizing agent, 2-iodoxybenzoic acid.  Gallen et al.13 investigated the 
acidity of 2-iodoxybenzoic acid in different solvents and it was found that 2-
iodoxybenzoic acid has a pKa value of 2.4 in water and 6.65 in DMSO. Since DMSO was 
the solvent used for dissolving the 2-iodoxybenzoic aicd for the reaction, the reaction 
conditions would be slightly acidic. This would favour the movement of the carbon-carbon 
double bond to the conjugated positions. The three products obtained had the same Rf 
value as one would expect but the 1H NMR spectrum of the mixture confirmed the 





the three different aldehyde proton at δH 9.70, 9.83 and 9.78.  In addition to this, mass 
spectral analysis of the mixture gave a single mass of [M + Na]+ equal to 319.1311 m/z, 
since all three compounds formed would have the same molecular mass. This confirms 
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Scheme 3.19. Carbon-carbon double bond movement 
 
3.4.2.1 Modification of C5-moiety 
 
Having failed the successful oxidation of compound 117 to form 118 as the sole product, 
we had to modify our synthetic route, for the synthesis of C5-moiety (88). The new 
synthetic route that was put forth is shown in Scheme 3.20. In this synthetic route the 
terminal hydroxy group of compound 117 would be protected as the silyl ether prior to the 
osmium catalysed dihydroxyation of the double bond. This is necessary for the 










































Scheme 3.20. Synthetic route 2 
 
Compound 124 was synthesised in 65% yield using TBDMS-Cl and imidazol s the base. 
TBDMS was chosen for the protection of the free hydroxy group because it removal 
should not affect the acetyl protecting groups which would be introduced in the following 
synthetic steps. The 1H NMR spectrum (Plate 24a) of compound 125 had two singlets at δH 
0.06 and at 0.92, integrating to six protons and nine protons, respectively. These two peaks 
are characteristic of the silyl ether protecting group. 
Having successfully protected the terminal hydroxy group of compound 124, the next step 
was the osmium catalysed asymmetric dihydroxyation. Osmium catalysed asymmetric 
dihydroxyation (AD) provides a path to induce chirality in olefins14. The reagent used for 
this reaction was AD-mix α, which is a premix consisting of OsO4, a chiral ligand 
dihydroquinine (DHQ), phthalazine (PHAL) and K3Fe(CN)6 complex which acts as a 
co-oxident in the reaction14. The stereochemistry of the product obtained in this reaction 
depends on the type of chiral ligand that is used. Scheme 3.21 outlines the catalytic cycle 
proposed for the AD reaction. As can be seen from Scheme 3.21, OsO4 act  as the oxidant 
in the reaction and forms complex 127 which then undergoes hydrolysis, releasing the 
syn-diol and ligand to the organic layer. The hydrolysed osmium complex 128 is oxidised 























































Scheme 3.21. Catalytic cycle for asymmetric dihydroxylation 
 
Compound 125 was obtained in an excellent yield of 92% by utilizing the AD reaction. 
The presence of compound 125 was confirmed by 1H NMR spectroscopy (Plate 25a) 
which showed a multiplet at δH 2.72-2.89 corresponding to the CH(OH)CH(OH) signals. 
Furthermore the aliphatic proton signals of compound 125 are further upfield as compared 
with that of compound 124, due to the introduction of electron-donating hydroxy groups. 
As mentioned previously, the stereochemistry resulting from the AD reaction is dependent 
on the ligand that is used. According to Kolb et al., AD-mix α, leads to the 
R,R-stereoisomer, whereas AD-mix β leads to the S,S-stereoisomer, when a trans-alkene is 
dihydroxylated14. In AD-mix β the chiral ligand used is dihydroquinidine (DHQD) 
whereas in AD-mix α DHQ. Kamal et al. utilised AD-mix α to obtain the S,S-stereoisomer 
in 92% enantiomeric excess15. We utilised a chiral shift reagent to determine the ee value 
of the dihydroxylation reaction. A chiral shift reagent (EuFOD) was added to 125 in 
CDCl3 and an 
1H NMR spectrum was obtained. From the 1H NMR spectra (Plate 25c), two 
peaks of approximately equal intensity was observed for the CH3-Si protons, indicating the 
presence of a racemic mixture. Kamal and co-workers carried out the AD reaction at 0 °C 
but our reaction was done at room temperature. Thus the difference in reaction conditions 





investigation, at this point was to establish a synthetic route to the diarylheptanoid 17, we
did not do any further investigations on the enantioselectivity of the reaction.  
The next step of the synthesis was the protection of the two hydroxy groups of compound 
125 as acetate esters to form compound 126. The 1H NMR spectrum (Plate 26a) of 126 
showed two singlets at δH 2.01 and 2.12 which corresponds to the acetate protecting 
groups.  In addition to this, the mutiplet for CH(Ac)CH(Ac) signals moved downfield by 
0.19, due to the introduction of the electron-withdrawing etser groups. 
Having compound 126 in hand, we attempted to remove the silyl ether protecting group of 
compound 126 to form compound 127. Ammonium fluoride, which is an effective silyl 
cleavage agent, was used for this reaction. Firstly the reaction was carried out at room 
temperature by stirring 126 in MeOH in the presence of NH4F. This reaction did not lead 
to the deprotection of the silly group upon stirring for 24 h. However, when 126 was 
refluxed in MeOH in the presence of NH4F, the silyl group was cleaved. However, a 
mixture of products was formed in this reaction due to the migration of the acetyl group to 
the terminal hydroxy group (Scheme 3.22). Since compound 128 and 129 formed in the 
reaction had the same Rf values on a TLC plate, we were not able to isolate and purify the 
products formed. However, the 1H NMR and COSY spectra of the mixture of products 
confirmed the formation compounds 128 and 129. Due to the time limitation, we did not 































(128) (129)  
Scheme 3.22. Removal of the silyl protecting groups* 
                                               





Intramolecular acetyl migration can be either base or acid catalysed. In this case the 
fluoride ions are basic and thus catalyses the reaction.  The mechanistic detail of acetate 
ester migration provides a reasonable explanation for the results obtained. Scheme 3.23 
shows the possible mechanism by which the acetate migration might have occurred. The 
intramolecular attack of the terminal alcohol on the carbonyl carbon of the acetyl group on 
the C-3 position leads to a six-membered ring intermediate (130) which is 
thermodynamically stable. The formation of a stable intermediate would in turn favour the 
formation of compound 128. 
Once compound 128 is formed, the Ac group on the C-2 carbon of compound 128 
migrates to form compound 129 as shown in Scheme 3.33.The stable five membered ring 































































Scheme 3.23. Acetyl migration to form compound 128 and 129 
 
Having failed to deprotect the silyl group successfully to form the required alcohol, 127, 
protective group tuning had to be done. We decided to change the acetyl protecting groups 





new synthetic route for the synthesis of the modified C5-moiety (133) is shown in Scheme 
3.24.   Compound 117 was subjected to the AD-reaction to form the triol 131. The reaction 
gave a good yield of 89%. The peak on the 1H NMR spectrum of compound 131, which 
had a significantly different chemical shift from that of compound 117, was the multiplet 
at δH 5.46-5.55 (Plate 28a). This multiplet corresponds to the protons on the same carbon 
as the two tertiary alcohol groups. The peaks which resulted from the CH=CH group, for 
compound 117 were not seen on the 1H NMR spectrum of compound 131, thus confirming 




























Scheme 3.24. Synthetic route 3 
 
Compound 131 was then exposed to 2,2-dimethoxy propane in the presence of catalytic 
PTSA to form compound 132 in 90% yield. Only one regioisomer forms in this reaction. 
Three different rings can form: a seven-membered ring, a six membered ring or a five 
membered ring. As was reported by other workers in carbohydrate chemistry, the 
five-membered dioxolane is formed exclusively. Formation of compound 132 was 
confirmed using 1H NMR and 13C NMR spectroscopy.  The 1H NMR spectrum of 
compound 132 had two singlets at δH 1.34 and 1.37, integrating for three protons each, 
which correspond to the two methyl groups of the acetonide (Plate 29a).  
Having successfully synthesised alcohol 132, the next step was to oxidise compound 132
to the subsequent aldehyde, 133.  IBX was utilised for the oxidation reaction. This reaction 
proceeded in an excellent yield of 89% to form the required compound 133. The 1H NMR 






3.5 Attempted Coupling of C2-moiety and C5-moiety 
 
Upon the successful synthesis of the required C2-moiety (87) and the C5-moiety (133), we 
attempted to couple compound 87 and 133 using the HWE reaction to form the required 
diarylheptanoid (17). Scheme 3.25, outlines the proposed synthetic strategy for the 
synthesis of 17. The first reaction would be the HWE reaction in which an E-alkene bond 
is formed between the C2-moiety (87) and the C5-moiety (133), to form the seven carbon 
aliphatic chain. Then we planned on deprotecting the acetoxy ether group to form 
compound 135. The secondary hydroxy groups would then be protected as the acetate ester 
using Ac2O to form compound 136. The last step would be the deprotection of the benzyl 














































Scheme 3.25. Proposed synthetic route for diarylheptanoid, 17 
 
We commenced the above synthetic strategy with the HWE reaction. Unfortunately the 
required compound 134 was not obtained but it was seen that compound 133 underwent 
β-elimination to form compound 136 under the HWE reaction conditions (Scheme 3.26). 
Thus we altered the reaction conditions and utilised different bases for the reaction in order 
to prevent the rearrangement of 133. Scheme 3.25 outlines the different reaction conditions 
that were tested. The rearrangement of compound 133 to form 136 was seen under all the 






























(ii) DBU, 0 °C
(iii) NaH, -78 °C
(iv) n-BuLi, 0 °C
(i) NaH, r.t
(ii) DBU, 0 °C
(iii) NaH, -78 °C





Scheme 3.26: Attempted coupling of the C2-moiety and C5-moiety using HWE reaction 
 
The   structure of compound 136 was confirmed using 1H NMR and COSY spectra.  The 
depicted mechanism for β-elimination of compound 133 is shown in Scheme 3.27. Firstly, 
the acidic proton of compound 133 is abstracted by the base leading to the cleavage of the 
acetonide protecting group. This leads to the formation of intermediate 137. Then 
intermediate 137 undergoes an intramolecular nucleophilic reaction, in which the 
nucelophilic hydroxy group attacks the electrophilic carbonyl carbon leading to the 
formation of intermediate 138. Finally, removal of the acidic proton in intermediate 137, 






























3.5.1 HWE reaction utilising a lactol as the C5-moiety 
 
Having failed to successfully couple the C2-moiety (87) and C5-moiety (133) via HWE 
reaction, we decided to convert the C5-moiety (133) into the corresponding lactol (139).  In 
the total synthesis of renealtins A and B, Sabitha et l.12 used HWE reaction to couple the 
precursors to obtain the required product. In their synthesis, firstly the lactone was 
synthesised which was then converted to the subsequent lactol in-situ. Scheme 3.28 
outlines the synthesis followed by them. Sabitha et al.12 reported that the reaction 

















DIBAL-H , n-BuLi, -78  °C, 12 h
 
Scheme 3.28. HWE reaction of a lactol 
 
Scheme 3.29 outlines the reaction conditions under which the conversion of compound 
133 to the lactol 139 was firstly attempted.  The formation of lactol 139 from compound 
133 is a one-pot reaction. Under the acidic conditions the acetonide protecting group 
cleaves leading to the formation of compound 119. The nucleophilic hydroxy group on the 
C-2 carbon of compound 119 attacks the electophilic carbonyl carbon to form the lactol 
139 as shown in Scheme 3.30. 
The acetonide protecting group of compound 133 was removed under acidic conditions 
using MeOH as the solvent. The reaction took approximately 6 hrs to go to completion. On 
analysis of the product obtained from this reaction using 1H NMR it was found that the 
required lactol 139 did not form, instead compound 140 was isolated. Formation of 




















p-TsOH, MeOH, 25  °C, 6 hrs
(133) (139)
(140)  
Scheme 3.29. Formation of acetal 140 
 
Scheme 3.30 outlines the mechanism by which compound 140 was formed. Firstly, 
Compound 119 undergoes intramolecular nucleophilic reaction to form the hemiacetal 
139.  This reaction is in equilibrium but the position of the equilibrium lies almost 
completely on the side of the hemiacetal. Thus the amount of open chain hydroxy-
aldehyde (119) is negligible. Under acidic conditions hemiacetals undergo reactions with 
alcohols such as MeOH to form acetals.  The OH group of compound 139 is protonated by 
the acid in the reaction medium forming intermediate 141, which looses a water molecule 
to form 142. Intermediate 142 is attacked by the nucleophilic OH group of MeOH to form 

























































Having failed to synthesise the lactol 139 using MeOH as the solvent, we decided to 
change the solvent for the reaction. We have to use a non-nucleophilic solvent, in order to 
prevent the formation of the acetal. A method used by Angyal et .17 for the deprotection 
of an acetonide utilises a 1:1 aq. HCl/THF. We then decided to use this solvent system for 
the deprotection. Using this reaction condition the required compound 139 was obtained in 
85% yield (Scheme 3.31). The formation of lactol 139 was confirmed by 1H NMR and 13C 












1:1 IN HCl/THF, 25  °C, 12 hrs
85%
 
Scheme 3.31. Synthesis of compound 139
 
Having successfully synthesised compound 139, we attempted the HWE reaction with the 
lactol as shown in Scheme 3.32. Several attempts to couple compound 139 and 87 using 
HWE reaction failed to yield the required product. Instead a complex mixture of products 
was isolated each time. As mentioned previously, similar Wittig-type reactions have been 

























(2) ButOK, 35  °C
 
Scheme 3.32. HWE reaction utilising the lactol as the C5-moiety 
 
Aucagne et al.21 used the Wittig reaction to couple phenylthiomethylidine phosphorane 
with a variety of sugars, as shown in Scheme 3.33.  They reported that pyrano- or furano- 
lactols containing one or more hydroxy groups did not react with the Wittig ylide. Instead 
mixtures of products were obtained. Upon protection of the free hydroxy groups as benzyl 





conclusion that the protecting groups were crtitical for the Wittig reaction21. In contrast, 
other authors were able to obtain the Wittig product in the presence of one free hydroxy 











X= OH or OR  
Scheme 3.33. HWE reaction of a lactol 
 
Based on the observations made by Aucagne et al.21, the protection of the free hydroxy 
groups on compound 139 may lead to the successful coupling of the lactol (139) and 
phosphonate ester (87) to form the required seven-carbon aliphatic chain. 
Although a similar phosphonate was used successfully in a model HWE reaction (Section 
3.2.2, Scheme 3.8) it seems that the reaction conditions required for the HWE reaction 
using a phosphonate ylide which is not stabilised by a second electron-withdrawing group, 
are too harsh for the lactol 139. Harcken and Martin report that the basic HWE reactions 
conditions often lead to racemisation or cyclisation of the initially formed hydroxyenoates 
in sugar lactols19. 
At this point, it was clear that a Wittig-type reaction is not suitable for the formation of the 
trans-double bond. Thus a different approach will need to be considered. However, due to 




In conclusion, diarylheptanoids are biologically active molecules which exist in minute 
quantities in some plant species. Owing to their interesting biological activities, the total 
synthesis of these compounds which could provide an alternative source to these 
biologically active compounds, have been investigated extensively. In this work, we 





African medicinal plant Siphonochilus aethiopicus. The synthetic strategy used in this 
research was the C2-moiety + C5-moiety strategy.  
Since the targeted diarylheptanoid 17, contains a trans-carbon-carbon double bond, a 
stereoselective olefination reaction was chosen for the coupling of the two moieties. Thus 
trans-selective HWE reaction, which is a variant of the Wittig olefination was studied.  
The C2-moiety which is the Horner phosphate and the C5-moiety, were both synthesised 
from commercially available starting materials by using simple functional group 
transformation reactions. However, we were unable to couple the two moieties to form the 
required seven-carbon aliphatic chain using the HWE reactions. When the C5-moiety was 
an aldehyde, it was seen that it readily decomposed under the HWE reaction condition. 
Thus the C5-moiety was converted into the corresponding lactol which was then subjected 
to the HWE reaction. Even with this modification we were not able to successfully couple 
the two moieties. The reason for the failure encountered with the HWE reaction with the 
lactol may be due to the free hydroxy groups on the lactol. Thus protection of these free 
hydroxy groups may lead to the successful synthesis of the trans-seven-carbon aliphatic 
chain. 
Even though the synthesis of the targeted diarylheptanoid 17 was not achieved in this 
investigation, we have made valuable progress towards the total synthesis of this 
compound: 
•  A suitably substituted phenylethyl precursor was prepared for the C2-moiety + 
C5-moiety coupling strategy. Although the phosphonate derivative was not useful 
for the synthesis of the diarylheptanoid 17, it may be useful for the preparation of 
other natural products. 
•  Phenylethyl derivatives with the correct substitution pattern and relative 
stereochemistry were prepared as the C5-component of the synthetic strategy. 
 
3.7 Future Work 
  
Since the target compound was not successfully synthesised, there is scope for future work 
in this area. Most importantly, a method needs to be developed which could successfully 





of the target compound (17). Thus further investigation needs to be done on the HWE 
reaction in order to find suitable reaction conditions which would favour the formation of 
the E-alkene. For example, the effect of protecting the free hydroxy groups of compound 
137, on the HWE reaction needs to be investigated. In addition to this, the synthetic 
methodology developed during this investigation needs to be optimized. This includes 
optimizing the enantioselectivity of the dihydroxyation reaction.  
Other options which must be considered for the formation of the double bond are the Julia 
olefination and its variants and also metathesis with a Grubb’s catalyst. 
Upon the successful synthesis of the novel diarylheptanoid 17, its analogues need to be 
synthesised. This is important in order to study the possible anti-inflammatory activity of 
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4     Experimental procedures 
 




Thin-layer chromatography was performed on aluminium-backed 0.2 mm silica gel plates 
(Merck Silica gel 60 F254). Normal and flash chromatography were done using Merck 
Kieselgel 60 silica with particle size 200-400 mm and on columns varying from 1 cm to 6 cm 
in diameter. Centrifugal chromatography was performed on a Harrison Research 
Chromatotram, on glass plates coated with 2 or 4 mm Merck silica gel 60 with particle size 
0.040-0.063 mm. 
 
4.1.2 Spectroscopic and Physical Data 
 
All melting points were obtained on a Reichert hot-stage microscope. 
Nuclear magnetic resonance spectroscopy (NMR) of the isolated compounds was done on a 
Bruker Avance lll 400 MHz spectrometer. All NMR spectra were recorded at 30 ○C in 
deuterated solvents and chemical shifts were recorded in ppm referenced to the solvent shift. 
Mass spectra were obtained using a Waters LCT Premier mass spectrometer using positive or 
negative electroscopy ionization (high resolution) and or a ThermoFinnigan Trace GC coupled 
to PolarisQ mass spectrometer (low resolution). 





4.1.3 Solvents and chemicals 
 
All the required chemicals were obtained from Fluka, Sigma-Aldrich or Merck and used 
without further purification unless otherwise specified. 
Anhydrous solvents were obtained from a Pure-Solv Solvent Purification System supplied by 
Innovative Technology, Inc. Water and oxygen present in the solvent are removed effectively 
using this system to produce dry deoxygenated high-purity solvents by passing through 
activated columns under low pressure to remove trace impurities.  Hexane used for column 
chromatography was distilled under reduced pressure prior to use. ‘Hexane’ refers to a 

















4.2 Synthetic Procedures 
 















A solution of (2-bromoethyl)benzene (2.07 g, 11 mmol) and triphenylphosphine (3.08 g, 
12 mmol) in anhydrous toluene (25 mL) was refluxed for 48 h. After cooling, the upper 
solvent layer was removed and the residue obtained was washed with toluene (2 x 10 mL) 
followed by ether (10 mL). The glassy solid obtained was dried under vacuum. The resulting 
phosphonium salt (92) was obtained as a hygroscopic, glassy compound (yield 4.95 g, 99%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.08 (2H, m, Ar-CH2-CH2-P), 4.22 (2H, m, Ar-CH2-
CH2-P), 7.24 (5H, m, H-Ar-CH2), 7.78 (15H, m, P-Ar-H). (Plate 1a) 
13C NMR (100 MHz, CDCl3) δC: 24.8 (Ar-CH2-CH2), 28.5 (d, JPC = 3.6 Hz, Ar-CH2-
CH2), 128.3 (C-5), 128.4 (C-4), 128.8 (d, JPC = 16.7 Hz, C-3), 130.6 (d, JPC = 12.6 Hz, 
C-7), 133.9 (d, JPC = 9.9 Hz C-6), 135.1 (d, JPC = 2.9 Hz, C-1). (Plate 1b) 





















(2-Bromoethyl)benzene  (5.0 mL, 37.0 mmol) and triethyl phosphite (8.3 mL, 48.0 mmol) in a 
50 mL round-bottomed flask was refluxed vigorously for 16 h. The flask was then allowed to 
cool and the excess triethyl phosphite was removed by distillation under vacuum. The crude 
product obtained was purified using column chromatography to yield the diethyl 
2-phenylethyphosphonate (97) as a yellow oil (yield 8.50 g, 98 %). 
  
1H NMR (400 MHz, CDCl3) δH: 1.30 (t, 6H, CH3-CH2-O), 1.94-2.14 (m, 2H, Ar-CH2-
CH2), 2.80-3.02 (m, 2H, Ar-CH2-CH2), 4.15 (q, 4H, O-CH2-CH3), 7.10-7.40 (m, 5H, 
Ar-H). (Plate 2a) 
13C NMR (100 MHz, CDCl3) δC: 16.4 (d, JPC = 5.9, Hz, POCH2CH3), 27.6 (d, JPC = 
139.7 Hz, Ph-CH2CH2P), 28.6 (d, JPC = 4.3 Hz, Ph-CH2CH2P), 61.7 (d, JPC = 6.6 Hz, 
POCH2CH3), 126.2 (C-4), 128.1 (C-2) 128.6 (C-3), 141.0 (d, JPC = 17.5 Hz, C-1). 
(Plate 2b) 


























2-Phenylethyltriphenylphosphonium bromide (92) (1.00 g, 2.0 mmol) was suspended in 
tetrahydrofuran (10 mL) and ether (6 mL) and stirred with butyllithium (BuLi)  (0.23 mL, 
2.0 mmol) for 1 h at room temperature. The solution was cooled to -70 °C and benzaldehyde 
(0.26 mL, 2.3 mmol) was added, the mixture was stirred vigorously for 15 min. Then BuLi 
(0.23 mL, 2.0 mmol) was added again and the reaction mixture was kept at -30 °C for 15 min. 
The solution was then treated with ethereal hydrogen chloride (2.2 mmol) and potassium 
t-BuOH (0.3 g, 3.0 mmol). The mixture was stirred at room temperature for 16 h, centrifuged, 
and the clear supernatant liquor was poured off and solvent evaporated. The crude product so 
obtained was purified using column chromatography (9:1 hexane/EtOAc) to afford a 
yellowish oil containing both 1,3-diphenyl-1-propene (E) and (Z) isomers (93) (yield 0.302 g, 
70%, Z:E = 8:2 ) 
 
1H NMR (400 MHz, CDCl3) δH: 3.72 (2H, d, 7.47 Hz, Ar-CH2-CH=CH), 5.91 (1H, dt, 
7.35Hz and 3.54Hz, Ar-CH2-CH=CH), 6.63 (1H, d, J= 11.6Hz, Ar-CH2-CH=CH), 
7.27 (5H, m, CH=CH-Ar-H), 7.37 (5H, m, H-Ar-CH2-CH). (Plate 3a) 
13C NMR (400 MHz, CDCl3) δC: 34.7 (C-3), 126.1 (C-8’), 126.8 (C-2’), 128.3 (C-3’), 
128.4 (C-7’), (C2’), 128.5 (C-5’),128.7 (C-4’), 130.0 (C-1), 130.7 (C-2), 137.3 (C-1’), 











To a stirred solution of diethyl 2-phenylethylphosphonate (97) (0.7 g, 2.7 mmol) in dry THF 
(10 mL) at 0 °C was added NaH (0.2 g, 7.7 mmol) in small portions.  After the suspension has 
warmed to room temperature, benzyldehyde (2.57 mmol, 0.26 mL) was added all at once. The 
reaction was then refluxed until all the starting material was consumed (TLC monitoring). The 
reaction mixture was diluted with water and extracted with Et2O (3 x 20 mL). The combined 
organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated in 
vacuo. The crude product was then purified using column chromatography (9:1 
hexane/EtOAc) to afford (E)-1,1-prop-1-ene-1,3-diyldibenzene (93) as a yellow oil (yield 0.20 
g, 41%,). 
 
1H NMR (400 MHz, CDCl3) δH: 3.70 (2H, d, 6.71 Hz, Ar-CH2-CH), 6.48 (1H, dt, 
6.58Hz and 2.53Hz, Ar-CH2-CH=CH), 6.58 (1H, d, 15.8Hz, Ar-CH2-CH=CH), 
























3,4,5-Trihyhydroxybenzoic acid (20.0 g, 117.6 mmol) was dissolved in dry methanol and 
conc. H2SO4 (1.0 mL) was added. This mixture was refluxed for 24 h and the solvent 
evaporated to yield a white solid. This residue was dissolved in Et2O (20 mL) and washed 
with saturated NaHCO3 solution and brine. The resulting organic phase was dried over 
anhydrous MgSO4 and concentrated in vacuo to afford the desired product which was then 
recrystallized in water to yield the pure white crystalline solid of methyl 3,4,5-
trihydroxybenzoate (99) (yield 19.5 g,  97%). 
 
1H NMR (400 MHz, DMSO-d6) δH: 3.74 (s, 3H, CO2,CH3), 6.93 (s, 2H, Ar-H). 
(Plate 5a) 
13C NMR (100 MHz, DMSO-d6) δC: 52.0 (OCH3), 109.0 (C-2), 119.8 (C-1), 138.9 
(C-4), 146.0 (C-3), 166.8 (COOCH3). (Plate 5b) 
MS (m/z): 183.90 
IR νmax (cm
-1):  3330 (OH), 1683 (C=O),  
Melting point (H2O): 183-184 




























A mixture of methyl 3,4,5-trihydroxybenzoate (99) (5.0 g, 20.8 mmol), triethyl orthoformate 
(6.0 g, 40.5 mmol) and Amberlyst 15E (0.6 g) in toluene was refluxed for 4 h with azeotropic 
removal of the EtOH/toluene mixture using a Dean-Stark trap. The reaction mixture was then 
filtered and concentrated in vacuo. Subsequent column chromatography (5:5 hexane/EtOAc) 
of the crude mixture yielded methyl 3-hydroxy-4,5-(ethoxymethylenedioxy)benzoate (100) as 
a white solid which was recrystalised from MeOH (yield 6.04 g, 92%). 
 
1H NMR (400 MHz, DMSO-d6) δH: 1.17 (t, 3H, J = 7.3Hz, OCH2CH3), 3.70 (q, 2H, J 
= 7.1 Hz, OCH2CH3), 3.79 (s, 3H, OCH3), 7.00 (d, 1H, J = 1.6 Hz, H2’), 7.16 (s, 1H, 
CHO3CH2CH3), 7.19 (d, 1H, J = 1.6 Hz, H1’).  
13C NMR   (100 MHz, DMSO-d6) δC: 14.8(CH3CH2O), 52.3 (OCH3), 59.7 
(OCH2CH3), 102.7(C-6), 113.9 (CO3CH2),) 120.0 (C-1), 124.3(C-2), 137.1 (C-4), 
138.8 (C-5), 147.2 (C-3), 166.7 (COOCH3).  
MS (m/z): 240 
IR νmax (cm
-1): 3298 (OH), 1696 (C=O) 


























To a solution of methyl 3-hydroxy-4,5-(ethoxymethylenedioxy)benzoate (100) (6.3 g, 
26.2 mmol) in MeCN (30 mL) was added potassium carbonate (6.8 g, 52.5 mmol) and benzyl 
bromide (6.8 g, 39.3 mmol). This mixture was stirred at 70-80 ○C for 12 h. After completion 
of the reaction as determined by TLC monitoring, the reaction mixture was diluted with water 
and extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine, 
dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was then purified 
using column chromatography (8:2 hexane/EtOAc) to yield methyl 3-benzyloxy-4,5-
(ethoxymethylenedioxy)benzoate (101) as a orange oil (yield 6.8 g, 79%). 
 
1H NMR (400 MHz, DMSO-d6) δH: 1.28 (t, 3H, J= 7.1 Hz, OCH2CH3), 3.73 (q, 2H, 
J= 7.3 Hz, OCH2CH3), 3.89 (s, 3H, OCH3), 5.24 (s, 2H, OCH2), 6.97 (s, 1H, 
CO3HCH2), 7.28 (s, 1H, H-6), 7.36-7.50 (m, 6H, Ar-H and H-2). (Plate 6a) 
13C NMR   (100 MHz, DMSO-d6) δC: 14.8 (CH3CH2O), 52.3 (OCH3), 59.7 
(OCH2CH3), 71.1 (OCH2Ar), 103.8 (C-6), 112.3 (CO3CH2), 120.1 (C-1), 124.4 (C-2), 



























A 2N HCl (10 mL) solution was added dropwise to a solution of methyl 3-benzyloxy-4,5-
(ethoxymethylenedioxy)benzoate (101) (5.5 g, 16.7 mmol) in MeOH (20 mL) over 10 min at 
room temperature. This mixture was then stirred for 2-3 h. The resulting white precipitate, 
methyl 3-benzyloxy-4,5-dihydroxybenzoate (102) was filtered and recrystalised from MeOH 
(yield 4.2 g, 93%). 
 
1H NMR (400 MHz, DMSO-d6) δH: 3.74 (s, 3H, CO2CH3), 5.16 (s, 2H, OCH2), 7.34 
(s, 1H, H-6), 7.37 (s, 1H, H-2), 7.38-7.47 (m, 5H Ar-H). (Plate 7a) 
13C NMR   (100 MHz, DMSO-d6) δC: 52.0 (OCH3), 71.6 (OCH2), 106.2 (C-2), 111.2 
(C-6), 121.9 (C-1), 128.1 (C-9), 128.7 (C-10), 128.8 (C-8) 135.8 (C-7), 137.1 (C-4) 
143.6 (C-5), 145.6 (C-3), 166.8 (COOCH3). (Plate 7b) 
MS (m/z): 274.10 
IR νmax (cm
-1): 3458 (OH) 



























To a solution of methyl 3-benzyloxy-4,5-dihydroxybenzoate (102) (4.0 g, 14.5 mmol) in 
MeCN (20 mL) was added potassium carbonate (3.8 g, 29.2 mmol) and methyl iodide (5.1 g, 
36.3 mmol). This mixture was stirred at 70-80 ○C for 12 h. After completion of the reaction as 
observed by TLC monitoring, the reaction mixture was diluted with water and extracted with 
Et2O (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous 
MgSO4 and concentrated in vacuo. The crude product was then purified using column 
chromatography (8:2 hexane/EtOAc) to yield methyl 3-benzyloxy-4,5-dimethoxybenzoate 
(103) as a white solid (yield 4.0 g, 91%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.91 (s, 3H, OCH3), 3.92(s, 3H, OCH3), 3.94(s, 3H, 
CO2CH3), 5.17 (s, 2H, OCH2), 7.32-7.48 (m, 6H, Ar-H). (Plate 8a) 
13C NMR   (100 MHz, CDCl3) δC: 52.2(OCH3), 56.3(OCH3), 60.9(OCH3), 
71.3(OCH2), 107.2 (C-6), 109.0 (C-2), 125.0(C-1), 127.4 (C-9), 128.0 (C-10), 128.6 
(C-8), 136.7(C-7), 143.0 (C-4), 152.1 (C-3), 153.2 (C-5), 166.7(COOCH3). (Plate 8b) 
ER+-HRMS m/z [M + Na]+: 325.1049  
                    (Calculated for C17H18O5+Na, 325.1052) 
IR νmax (cm
-1): 1711 (C=O) 

























A solution of 3-benzyloxy-4,5-dimethoxybenzoate (103) (3.8 g, 12.5 mmol) in dry THF 
(10 mL) was added dropwise to a stirred solution of LiAlH4 (0.5 g, 12.5 mmol) in dry THF 
(10 mL) at 0 °C under N2 atmosphere. This mixture was then stirred at room temperature until 
the reaction was complete (2-3 h, TLC monitoring). The excess hydride was quenched with 
H2O followed by aqueous (10%) H2SO4 (10 mL). This mixture was then extracted with Et2O 
(3 x 20 mL). The combined organic layers were washed with saturated aqueous NaHCO3 
(30 mL), brine (30 mL), dried over Anhydrous MgSO4 and concentrated in vacuo. The crude 
product was then purified using column chromatography (5:5 hexane/EtOAc) to afford 
3-benzyloxy-4,5-dimethoxyphenylmethanol (104) as a colourless oil (yield 2.9 g, 84%). 
1H  NMR (400 MHz, CDCl3) δH: 3.84 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 4.56 (s, 2H, 
CH2OH), 5.11 (s, 2H, OCH2), 6.59 (s, 1H, H-6), 6.63 (s, 1H, H-2), 7.29-7.46 (m, 5H,  
Ar-H). (Plate 9a) 
13C NMR   (100 MHz, CDCl3) δC: 56.1 (OCH3), 60.9 (OCH3), 65.2 (CH2OH), 71.2 
(OCH2), 104.3 (C-6), 106.1 (C-2), 127.3 (C-9), 127.9 (C-10), 128.9 (C-8), 136.7 (C-1), 
137.1 (C-7), 138.0(C-4), 152.5 (C-3), 153.0 (C-5). (Plate 9b) 
ER+-HRMS m/z: 297.1077 [M + Na]+       
       (calculated for C16H18O4+Na, 297.1078) 
IR νmax (cm





















KBrO3 (8.0 g, 48 mmol) was dissolved in H2SO4 (2 M, 76 mL) in a two-necked round bottom 
flask equipped with a magnetic stirrer bar, reflux condenser and thermometer. The clear 
solution was heated to 60 °C and o-iodobenzoic acid (8.00 g, 32 mmol) was added over 
40 min in small (0.5 g) portions. The mixture became a bright orange colour as Br2 gas was 
evolved and a white precipitate formed. After the addition was complete, the temperature was 
maintained at 65 °C for 3 h. The solution was then cooled in an ice bath and the solid material 
was collected by vacuum filtration with a Buchner funnel and flask. The white precipitate was 
washed with cold H2O (1000 mL), cold EtOH (1000 mL) followed by cold water (1000 mL). 
The IBX was air dried and weighed (yield 8.2 g, 29 mmol, 91%). 
 
 
1H NMR (400 MHz, DMSO-d6) δH: 7.83 (1H, t, J = 8.3 Hz, H-3), 7.98 (1H, t, J = 8.3 
Hz, H-2), 8.02 (1H, d, J = 12.8 Hz, H-4), 8.14 (1H, d, J = 12.8 Hz, H-1).  
 
13C NMR (400 MHz, DMSO-d6) δC: 125.5 (C-1), 130.6 (C-4), 131.6 (C-4a), 133.5 





























To a stirred solution of 2-iodoxybenzoic acid (IBX) (3.0 g, 11.0 mmol) in DMSO (10 mL), 
was added a solution of the alcohol, 3-benzyloxy-4,5-dimethoxyphenylmethanol (104)  (2.0 g, 
7.4 mmol) in THF (20 mL) at room temperature and was stirred for 3 hours. After completion 
of the reaction as observed by TLC monitoring, water (10 mL) was added to the reaction 
mixture and the precipitated solid was filtered off. The filtrate was diluted with water (20 mL) 
and extracted with ether (3 x 20 mL). The combined organic layers were washed successively 
with NaHCO3, water, brine and dried over anhydrous MgSO4. The solvent was removed under 
reduced pressure and the crude product was purified using column chromatography (7:3 
hexane/EtOAc) to afford the desired product, 3-benzyloxy-4,5-dimethoxybenzaldehyde  (105) 
as a white solid (yield 1.99 g, 96%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.94 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 5.20 (s, 2H, 
OCH2), 7.16 (s, 1H, H-6), 7.19 (s, 1H, H-2), 7.33-7.48 (m, 5H, Ar-H), 9.84 (s, 1H, 
COH). (Plate 10a) 
13C NMR   (100 MHz, CDCl3) δC: 56.3 (OCH3), 61.0 (OCH3), 71.3 (OCH2), 106.7 
(C-6), 109.3 (C-2), 127.4 (C-9), 128.2 (C-10), 128.6 (C-8), 131.7 (C-1), 136.5 (C-7), 
144.4 (C-4), 152.7 (C-3), 153.9 (C-5), 190.9 (COH). (Plate 10b) 
ER+-HRMS m/z: 295. 0945 [M + Na]+      






-1): 1684 (C=O), 1110 (C-O) 
Melting point (Et2O): 56-57 °C 
 

















NaH was added to a stirred suspension of the methyltriphenylphosphonium iodide (3.5 g, 
8.8 mmol) in dry THF (20 mL) containing 3-(benzyloxy)-4,5-dimethoxybenzaldehyde (105) 
(1.9 g, 6.9 mmol). The suspension was stirred for 5 h at room temperature and was poured into 
ice water and extracted with Et2O (3 x 10 mL). The combined organic layer was dried over 
anhydrous MgSO4 and concentrated in vacuo.  The crude product was purified using column 
chromatography (7:3 hexane/EtOAc) to afford the desired product, 1-benzyloxy-2,3-
dimethoxy-5-vinylbenzene (106) as a yellow oil (yield 1.31 g, 70%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.90 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.17 (s, 2H, 
OCH2), 5.21 (d, 1H, J=10.8 Hz, CHCH2), 5.63 (d, 1H, J=17.5 Hz, CHCH2), 6.62 (dd, 
2H, J=17.5 Hz, CHCH2), 6.67 (s, 1H, H-6), 6.71 (s, 1H, H-4), 7.33-7.50 (m, 5H, Ar-
H). (Plate 11a) 
13C NMR   (100 MHz, CDCl3) δC: 56.1 (OCH3), 60.4 (OCH3), 61.0, 71.3 (OCH2-Ar), 
103.8 (C-4), 105.9 (C-6), 113.2 (CH 2), 127.3 (C-9), 127.9 (C-10), 128.5 (C-8), 






ER+-HRMS m/z: 293.1158 [M + Na]+       
    (Calculated for C17H18O3+Na, 293.1154) 
IR νmax (cm
-1): 1579 (C=C), 1112 (C-O).  
 


















A dry flask equipped with a magnetic stirrer bar and a reflux condenser was flushed with 
nitrogen and maintained under a positive nitrogen pressure. The flask was then charged with 
1-benzyloxy-2,3-dimethoxy-5-vinylbenzene (106) (1.1 g, 3.4 mmol) in dry THF (20 mL) and 
cooled to 0 °C with an ice-water bath. This was followed by dropwise addition of a borane-
methyl sulfide (BMS) (0.1 g, 1.3 mmol). The cooling bath was removed and the solution was 
stirred for 3 hours at room temperature. 3N NaOH (0.5 mL) was then added and the reaction 
cooled to 0°C. This was followed by dropwise addition of hydrogen peroxide (0.5 mL of 30% 
aqueous solution). The reaction mixture was refluxed for 1 h and was poured into ice water 
(20 mL). The mixture was then extracted with Et2O (3 x 10 mL). The combined organic layers 
was washed with brine, dried over anhydrous MgSO4 and concentrated under reduced 
pressure. The crude product was purified using column chromatography (5:5 hexane/EtOAc) 
to afford the desired product, (3-benzyloxy-4,5-dimethoxyphenyl)ethanol (107) as a yellow oil 






1H NMR (400 MHz, CDCl3) δH: 2.78 (t, 2H, 6.50Hz, CH2CH2OH), 3.81 (t, 2H, 6.42 
Hz, CH2CH2OH), 3.87 (s, 3H, OCH3), 3.88(s, 3H, OCH3), 5.14 (s, 2H, OCH2), 6.47 
(s, 1H, H-6), 6.50 (s, 1H, H-2), 7.30-7.46 (m, 5H, Ar-H). (Plate 12a) 
13C NMR  (100 MHz, CDCl3) δC: 39.5 (CH2CH2OH), 56.2 (OCH3), 60.9 (OCH3), 63.5 
(CH2OH), 71.2 (OCH2), 106.5 (C-6), 108.4 (C-2), 127.4 (C-9), 127.9 (C-10), 128.5 
(C-8), 134.1 (C-1), 137.2 (C-7), 137.6 (C-4), 152.4 (C-3), 153.6 (C-5). (Plate 12b) 
ER+-HRMS m/z: 311.1257 [M + Na]+ 
   (Calculated for C17H20O4+Na, 311.1259) 
IR νmax (cm
-1): 3450 (OH), 1112 (C-O) 
 


















A solution of phosphorous tribromide (0.2 g, 0.9 mmol) in dry Et2O (5 mL) was added 
dropwise to a stirred solution of 2-(3-benzyloxy-4,5-dimethoxyphenyl)ethanol (107) (0.6 g, 
2.2 mmol) in dry Et2O (15 mL) at 0 °C over 15 min. The mixture was stirred at room 
temperature for 1 h and was then quenched with water. The aqueous layer was extracted with 
ether (2 x 10 mL). The combined organic layers were washed with NaHCO3 followed by 
brine, dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was 
purified using column chromatography (8:2 hexane/EtOAc) to afford the desired product, 







1H NMR (400 MHz, CDCl3) δH: 3.08 (t, 2H, J=6.50Hz, CH2CH2Br), 3.53 (t, 2H, J = 
6.42 Hz, CH2CH2Br), 3.87 (s, 3H, OCH3), 3.88(s, 3H, OCH3), 5.14 (s, 2H, OCH2), 
6.45 (s, 1H, H-4), 6.48 (s, 1H, H-6), 7.38-7.47 (m, 5H, Ar-H). (Plate 13a) 
13C NMR (100 MHz, CDCl3) δC: 32.6 (CH2CH2Br), 39.7 (CH2CH2Br) 56.2 (OCH3), 
60.9 (OCH3), 71.3 (OCH2), 106.3 (C-4), 108.2 (C-6), 127.3 (C-9), 127.9 (C-10), 128.6 
(C-8), 134.5 (C-5), 137.2 (C-7), 137.9 (C-2), 152.5 (C-1), 153.5 (C-3). (Plate 13b) 
ER+-HRMS m/z: 373.0411 [M + Na]+  
                            (Calculated for C17H19O3Br+Na, 373.0415) 
IR νmax (cm
-1): 1108 (C-O) 
 





















1-(benzyloxy)-5-(2-bromoethyl)-2,3-dimethoxybenzene (108) (0.5 g, 1.3 mmol) was refluxed 
in triethyl phosphonate (5 mL) for 16 h. After the completion of the reaction as determined by 
TLC monitoring, excess triethyl phosphonate was distilled off under vacuum and the crude 
product obtained was purified using column chromatography (7:3 hexane/EtOAc) to yield the 
Horner-Wittig phosphate, (87) as a yellow oil (yield 0.37 g, 73%) 
 
1H NMR (400 MHz, CDCl3) δH: 1.34 (t, 6H, J = 7.20 Hz, POCH2CH3), 1.97-2.08 (m, 





4H, J = 7.51 Hz, POCH2CH3) 5.13 (s, 2H, OCH2), 6.45 (s, 1H, Ph-H), 6.47 (s, 1H, Ph-
H), 7.30-7.46 (m, 5H, Ar-H). (Plate 14a) 
13C NMR (100 MHz, CDCl3) δC: 16.5 (d, JPC = 6.4 Hz, OCH2CH3,), 27.7 (d, JPC = 
139.2 Hz, Ph-CH2CH2P), 28.9 (d, JPC = 4.4 Hz, Ph-CH2CH2P),  56.2 (OCH3), 60.9 
(OCH3), 61.6 (d, JPC = 6.3 Hz OCH2CH3), 71.2 (OCH2), 105.6 (C-2), 107.5 (C-6), 
127.3 (C-9), 127.8 (C-10), 128.5 (C-8), 136.5 - 136.7 (d, JPC = 17.4 Hz, C-1), 137.2 
(C-7), 137.4 (C-4)), 152.4(C-3), 153.5 (C-5). (Plate 14b) 
31P NMR δP (162 MHz, CDCl3): 30.56 (s, 1P) (Plate 14c) 
 

















To a solution of 4-hydroxy-3-methoxybenzaldehyde (6.0 g, 39.4 mmol) in MeCN (100 mL) 
was added potassium carbonate (10.9 g, 79.3 mmol) and benzyl chloride (5.5 g, 43.7 mmol). 
This mixture was stirred at 70-80 °C for 12 h. After completion of the reaction, as observed by 
TLC monitoring, the reaction mixture was poured into distilled water (50 mL) and extracted 
with EtOAc (3 x 20 mL). The combined organic layers were washed successively with water, 
brine, dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was 
purified using column chromatography (7:3 hexane/EtOAc) to yield 4-benzyloxy-3-
methoxybenzaldehyde (110) as white crystals (yield 8.1 g, 85%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.96 (s, 3H, OCH3), 5.26(s, 2H, OCH2), 7.00 (d, 1H, 





13C NMR   (100 MHz, CDCl3) δC: 56.1 (OCH3), 70.9 (OCH2), 109.6 (C-2), 112.5 
(C-5), 126.5 (C-6), 127.2 (C-9), 128.2 (C-10), 128.7, (C-8), 130.4 (C-1), 136.1 (C-7), 
150.2 (C-3), 153.7 (C-4), 190.9 (COH). (Plate 15b) 
ER+-HRMS m/z: 265.0837 [M + Na]+       
      (Calculated for C15H14O3+Na, 265.0841) 
IR νmax (cm
-1): 1671 (C=O), 1131 (C-O) 
Melting point (Et2O): 54-55 °C (lit.
12 60-61 °C (EtOAc)) 
 

















To a stirred solution of triethyphosphoacetate (9.3 g, 41.3 mmol) in dry THF (50 mL) at 0 °C 
was added NaH (1.0 g, 41.3 mmol). This mixture was stirred at 0 °C for 30 min followed by 
the dropwise addition of 4-benzyloxy-3-methoxybenzaldehyde (110) (5.0 g, 20.6 mmol)  in 
dry THF (10 mL) and the reaction mixture was stirred at room temperature for 1 h. The 
reaction was then quenched with saturated aqueous NH4Cl solution (10 mL) and extracted 
with Et2O (3 x 20 mL). The combined organic layers were then washed with brine and 
concentrated in vacuo. The crude product was purified using column chromatography 
(8:2 hexane/EtOAc) to yield ethyl 4-benzyloxy-3-methoxycinnamate (111) as white crystals 
(yield 6.21 g, 97%). 
1H NMR (400 MHz, CDCl3) δH: 1.35 (t, 3H, J=7.2 Hz, OCH2CH3), 3.92 (s, 3H, 





CHCHCOO), 6.88 (d, 1H, J=8.4 Hz, H-6), 7.04 (d, 1H, J= 8.87, H-5), 7.08 (s, 1H, 
H-2), 7.23-7.46 (m, 5H), 7.63 (d, 1H, J=15.9 Hz, CHCHCOO). (Plate 16a) 
13C NMR (100 MHz, CDCl3) δC: 14.0 (COOCH2CH3), 56.1 (OCH3), 60.5 
(COOCH2CH3), 71.0 (OCH2), 110.3 (C-2), 113.6 (C-5), 116.2 (CH COO), 122.4 
(C-6), 127.3 (C-9), 127.9 (C-10), 128.1 (C-1), 128.7 (C-8), 136.7 (C-7), 144.6 
(CHCHCOO), 149.9 (C-4), 150.4 (C-3), 167.2 (COOCH2CH3). (Plate 16b)  
ER+-HRMS m/z: 335.1478 [M + Na]+ 
                                        (Calculated for C19H18O4+Na, 335.1479) 
IR νmax (cm
-1): 1698 (C=O), 1159 (C-O), 1600 (C=C) 
Melting point (pet. Ether): 62 °C (lit.14 64 °C) 
 

















Ethyl 4-benzyloxy-3-methoxycinnamate (111) (2.0 g, 6.4 mmol) was dissolved in absolute 
EtOH (20 mL) and catalytic amount of 10% Pd/C (2.5 mg) was added to this mixture. This 
mixture was then placed in a reactor with H2 gas at a pressure of 2 atm for 30 minutes. The 
reaction mixture was poured into water (20 mL) and extracted with Et2O (3 x 20 mL). The 
combined organic layers were washed with brine, dried over anhydrous MgSO4 and 
concentrated in vacuo. The crude product was purified using column chromatography 
(8:2 hexane/EtOAc) to yield Ethyl 3-(4-benzyloxy-3-methoxyphenyl)propanoate (112) as a 






1H NMR (400 MHz, CDCl3) δH: 1.25 (t, 3H, J=7.0 Hz, OCH2CH3),2.61 (t, 2H, J=7.97 
Hz, CH2CH2COO), 2.91 (t, 2H, J=7.7 Hz CH2CH2COO), 3.89 (s, 3H, OCH3), 4.14 (q, 
2H, J=7.1 Hz, OCH2CH3), 5.14 (s, 2H, OCH2),  6.69 (d, 1H, J=8.0 Hz, H-5), 6.76 (s, 
1H, H-2), 6.82 (d, 1H, J=8.1, H-6), 7.29-7.40 (m, 5H, Ar-H). (Plate 17a) 
13C NMR (100 MHz, CDCl3) δC: 14.2 (COOCH2CH3), 30.7 (CH2CH2COO), 36.2 
(CH2CH2COO), 56.0 (OCH3), 60.4 (COOCH2CH3), 71.3(OCH2), 112.4(C-2), 114.5 
(C-5), 120.2 (C-6), 127.4 (C-9), 127.8(C-10), 128.5 (C-8), 133.9 (C-1), 137.4 (C-7), 
146.7 (C-4), 149.7 (C-3), 172.9 (COO). (Plate 17b) 
ER+-HRMS m/z: 337.1714 [M + Na]+ 
                                        (Calculated for C19H18O4+Na, 337.1710) 
IR νmax (cm
-1): 1724 (C=O), 1149 (C-O) 
 
















A solution of ethyl 3-(4-benzyloxy-3-methoxyphenyl)propanoate (112) (15.0 g, 47.7 mmol) in 
dry THF (15 mL) was added dropwise to a stirred solution of LiAlH4 (1.8 g, 47.7 mmol) in 
dry THF (20 mL) at 0 °C under N2 atmosphere. This mixture was then stirred at room 
temperature until the reaction was complete (1-2 h, TLC control). The excess hydride was 
quenched with H2O followed by aqueous 10% H2SO4 (10 mL). This mixture was then 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with saturated 





evaporated in vacuo and the product purified using column chromatography 
(6:4 hexane/EtOAc) to yield 3-(4-benzyloxy-3-methoxyphenyl)propan-1-ol (113) as white 
solid (yield 11.53 g, 89%). 
 
1H NMR (400 MHz, CDCl3) δH: 1.89 (qr, 2H, J=6.7 Hz, CH2CH2CH2OH),2.67 (t, 2H, 
J=7.4 Hz CH2CH2CH2OH), 3.69 (t, 2H, J=6.3 Hz, CH2CH2CH2OH), 3.90 (s, 3H, 
OCH3), 5.14 (s, 2H, OCH2),  6.69 (d, 1H, J=8.0 Hz, H-5), 6.77 (s, 1H, H-2), 6.83 (d, 
1H, J=8.1, H-6), 7.30-7.47 (m, 5H, Ar-H). (Plate 18a) 
13C NMR (100 MHz, CDCl3) δC: 31.7 (CH2CH2CH2OH), 34.3 (CH2CH2CH2OH), 56.0 
(OCH3), 62.3 (CH2CH2CH2OH), 71.3 (OCH2), 112.5 (C-2), 114.5 (C-5), 120.3 (C-6), 
127.3 (C-9), 127.7 (C-10), 128.5 (C-8), 135.2 (C-1), 137.5 (C-7), 146.5 (C-4), 149.7 
(C-3). (Plate 18b) 
ER+-HRMS m/z: 295.1314 [M + Na]+  
   (Calculated for C17H20O3+Na, 295.1310) 
IR νmax (cm
-1): 3561 (OH), 1220 (C-O) 
Melting point (pet. Ether): 55 °C 
 

















To a stirred solution of 2-iodoxybenzoic acid (IBX) (16.3 g, 58.2 mmol) in DMSO (20 mL), 





38.8 mmol) in THF (30 mL) at room temperature and the resulting solution was stirred for 3 h. 
After completion of the reaction as observed by TLC monitoring, water (20 mL) was added to 
the reaction mixture and the precipitated solid was filtered off. The filtrate was diluted with 
water (20 mL) and extracted with ether (3 x 20 mL). The combined organic layers were 
washed successively with NaHCO3 solution, water, brine and dried over anhydrous MgSO4. 
The solvent was removed in vacuo and the crude product was purified using column 
chromatography (8:2 hexane/EtOAc) to afford the desired product, 3-(4-benzyloxy-3-
methoxyphenyl)propanal (114) as a white solid (yield 8.22 g, 79%). 
 
1H NMR (400 MHz, CDCl3) δH: 2.77 (t, 2H, J=7.1 Hz, CH2CH2COH),2.92 (t, 2H, 
J=7.5 Hz CH2CH2COH), 3.90 (s, 3H, OCH3), 5.14 (s, 2H, OCH2),  6.68 (d, 1H, J=8.2 
Hz, H-5), 6.76 (s, 1H, H-2), 6.83 (d, 1H, J=8.2, H-6), 7.32-7.47 (m, 5H, Ar-H), 9.83 
(s, 1H, CH2CH2COH). (Plate 19a) 
13C NMR (100 MHz, CDCl3) δC: 27.8 (CH2CH2COH), 45.4 (CH2CH2COH), 56.0 
(OCH3), 71.3 (OCH2), 112.4 (C-2), 114.50 (C-5), 120.1 (C-6), 127.3 (C-9), 127.8 
(C-10), 128.50 (C-8), 133.6 (C-1), 137.3 (C-7), 146.8 (C-4), 149.8 (C-3), 201.6 
(CH2CH2COH). (Plate 19b) 
ER+-HRMS m/z [M + Na]+: 325.1414 [M + Na]+ 
            (Calculated for C18H22O4+Na, 325.1416) 
IR νmax (cm
-1): 1709 (C=O), 1220 (C-O) 

























To a pyrex test tube attached to a reflux condenser was added 
3-(4-benzyloxy-3-methoxyphenyl)propanal (114) (6.0 g, 22.4 mmol), pyridine (10 mL), 
piperidine (20 mL) and  malonic acid (3.48 g, 34.0 mmol). The resulting mixture was 
irradiated with an output of 100 W using a microwave for 30 min. After completion of the 
reaction as observed by TLC monitoring, the reaction mixture was cooled to room 
temperature and neutralised with 1N HCl. The reaction mixture was then cooled to 0 °C and 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with brine, dried 
over anhydrous MgSO4 and concentrated in vacuo. The crude product was then purified using 
flash chromatography (2:8 hexane/EtOAc) to yield (E)-5-(4-benzyloxy-3-
methoxyphenyl)pent-3-enoic acid (115) as a yellow oil (yield 6.64 g, 95%). 
 
1H NMR (400 MHz, CDCl3) δH: 3.14, (d, 2H, J=7.2 Hz, CH2CHCHCH2COOH), 3.34 
(d, 2H, J=6.8 Hz, CH2CHCHCH2COOH), 3.90 (s, 3H, OCH3), 5.14 (s, 2H, OCH2), 
5.68-5.59 (m, 1H, CH2CHCHCH2COOH), 5.71- 5.89 (m, 1H, CH2CHCHCH2COOH), 
6.67 (d, 1H, J= 8.6 Hz, H-5), 6.79 (s, 1H, H-2), 6.83 (d, 1H, J= 8.2 Hz, H-6), 7.32-7.47 
(m, 5H, Ar-H). (Plate 20a) 
13C NMR (100 MHz, CDCl3) δC: 37.5 (CH2CHCHCH2COOH), 38.4 
(CH2CHCHCH2COOH), 56.0 (OCH3), 71.3 (OCH2), 112.5 (C-2), 114.4 (C-5), 120.4 
(C-6), 122.3 (CH2CHCHCH2COOH), 127.3 (C-9), 127.7 (C-10), 
CH2CHCHCH2COOH), 128.5(C-8), 133.3 (C-1), 134.0 (CH2CHCHCH2COOH), 





ER+-HRMS m/z: 335.1259 [M + Na]+  
                            (Calculated for C19H20O4+Na, 335.1259) 
IR νmax (cm
-1): 2959(O-H), 1692 (C=O), 1222 (C-O) 
 

















To a stirred solution of (3E)-5-(4-benzyloxy-3-methoxyphenyl)pent-3-enoic acid (115) (6.6 g, 
21.1 mmol) in MeOH (20 mL) at 0 °C was added BF3-Et2O (3.2 mL, 25.3 mmol). This 
mixture was stirred at room temperature for 2 h. After completion of the reaction as 
determined by TLC monitoring, the reaction mixture was diluted with water and extracted 
with Et2O (3 x 20 mL). The combined organic layers were washed with brine, dried over 
anhydrous MgSO4 and concentrated in vacuo. The crude product was then purified using flash 
chromatography (7:3 hexane/EtOAc) to yield (E)-methyl 
5-(4-benzyloxy-3-methoxyphenyl)pent-3-enoate (116) as a yellow oil (yield 5.58 g, 81%) 
 
1H NMR (400 MHz, CDCl3) δH: 3.10, (d, 2H, J=6.7 Hz, CH2COOCH3), 3.34 (d, 2H, 
J=6.4 Hz, CH2CHCHCH2COOCH3), 3.71 (s, 3H, OCH3),3.90 (s, 3H, COOCH3), 5.15 
(s, 2H, OCH2-Ar), 5.60-5.78 (m, 2H, CH2CHCHCH2), 6.68 (d, 1H, J= 8.1 Hz, H-5), 
6.76 (s, 1H, H-2), 6.84 (d, 1H, J= 8.2 Hz, H-6), 7.32-7.48 (m, 5H, Ar-H). (Plate 21a) 
13C NMR (100 MHz, CDCl3) δC: 37.7 (CH2CHCHCH2COOH), 38.5 
(CH2CHCHCH2COOH), 51.8 (COOCH3), 56.0 (OCH3), 71.3 (OCH2), 112.6 (C-2), 





128.4 (C-8), 133.4 (C-1), 133.5 (CH2CHCHCH2COOH) , 137.4 (C-7), 146.6 (C-4), 
149.8 (C-3), 172.3 (COOCH3). (Plate 21b) 
ER+-HRMS m/z: 349.1418 [M + Na]+  
    (Calculated for C20H22O4+Na, 349.1416) 
IR νmax (cm
-1): 1733 (C=O) 
 

















A solution of methyl (E)-5-(4-benzyloxy-3-methoxyphenyl)pent-3-enoate (116) (3.7 g, 
11.0 mmol) in dry THF (20 mL) was added dropwise to a stirred solution of LiAlH4 (0.5 g, 
13.7  mmol) in dry THF (10 mL) at 0 °C under N2 atmosphere. This mixture was then stirred 
at room temperature until the reaction was complete (2-3 h, TLC control). The excess hydride 
was quenched with H2O followed by 10% aqueous H2SO4 (10 mL). This mixture was 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with a saturated 
aqueous NaHCO3 solution (30 mL), brine (30 mL) and dried over anhydrous MgSO4. The 
solvent was then evaporated in vacuo and the product purified using column chromatography 
(5:5 hexane/EtOAc). (E)-5-(4-benzyloxy-3-methoxyphenyl)pent-3-en-1-ol (117) was isolated 
as a colourless oil (yield 2.93 g, 89%). 
 
 
1H NMR (400 MHz, CDCl3) δH: 2.32 (q, 2H, J=6.3 Hz, CH2CHCHCH2CH2OH), 3.32 





CH2CHCHCH2CH2OH), 3.89 (s, 3H, OCH3), 5.14 (s, 2H, OCH2), 5.46-5.55 (m, 1H, 
CH2CHCHCH2CH(OH)), 5.67-5.76 (m, 1H, CH2CHCHCH2CH(OH)), 6.67 (d, 1H, 
J=8.1 Hz, H-5), 6.75 (s, 1H, H-2), 6.83 (d, 1H, J=8.1 Hz, H-6), 7.28-7.48 (m, 5H, 
Ar-H). (Plate 22a) 
13C NMR (100 MHz, CDCl3)δC: 35.9 (CH2CHCHCH2CH2OH), 38.7 
(CH2CHCHCH2CH2OH), 56.0 (OCH3), 62.1 (CH2CHCHCH2CH2OH), 71.3 (OCH2), 
112.5 (C-2), 114.5 (C-5), 120.3 (C-6), 127.3 (C-9), 127.4 (CH2CHCHCH2CH2OH), 
127.7 (C-10), 128.5 (C-8), 132.6 (CH2CHCHCH2CH2OH), 133.9 (C-1), 137.4 (C-7), 
146.6 (C-4), 149.7 (C-3). (Plate 22b) 
ER+-HRMS m/z: 321.1469 [M + Na]+  
                            (Calculated for C19H22O3+Na, 321.1467) 
IR νmax (cm
-1): 3396 (OH), 1509 (C=C), 1220 (C-O) 
 
4.2.25  [(E)-5-(4-Benzyloxy-3-methoxyphenyl)pent-3-enoxy]-tert-butyl-

















To a stirred solution of (E)-5-(4-benzyloxy-3-methoxyphenyl)pent-3-en-1-ol (117) (2.9  g, 9.6 
mmol) in dry CH2Cl2 (10 mL) at 0 °C was added imidazol (1.3 g, 19.1 mmol) followed by 
TBDMS-Cl (3.24 g, 21.50 mmol). The reaction mixture was then stirred at room temperature 
for 6 h. The reaction was quenched with a saturated aqueous NH4Cl solution (10 mL) and 





(50 mL), brine (50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo 
and the purification of the crude product by flash chromatography (8:2 hexane/EtOAc) 
afforded [(E)-5-(4-Benzyloxy-3-methoxyphenyl)pent-3-enoxy]-tert-butyl-dimethylsilane  
(124) as a yellow oil (yield 2.42 g, 61%). 
 
1H NMR (400 MHz, CDCl3) δH: 0.06 (s, 6H, OSi(CH3)2C(CH3)3), 0.92 (s, 9H, 
OSi(CH3)2C(CH3)3), 2.28 (q, 2H, J=6.8 Hz, CH2CHCHCH2CH2OSi), 3.30 (d, 2H, 
J=6.7 Hz, CH2CHCHCH2CH2OSi), 3.67 (t, 2H, J=6.8 Hz, CH2CHCHCH2CH2OSi), 
3.90 (s, 3H, OCH3), 5.15 (s, 2H, OCH2-Ar), 5.48-5.56 (m, 1H 
CH2CHCHCH2CH2OSi), 5.60-5.69 (m, 1H, CH2CHCHCH2CH2OSi), 6.68 (d, 1H, 
J=8.4 Hz, H-5), 6.75 (s, 1H, H-2), 6.83 (d, 1H, J= 8.2 Hz, H-6), 7.30-7.50 (m, 5H, 
Ar-H). (Plate 23a) 
13C NMR   (100 MHz, CDCl3) δC: -5.2 (OSi(CH3)2), 18.4 (OSi(CH3)2C(CH3)3), 26.0 
(OSi(CH3)2C(CH3)3), 36.2 (CH2CHCHCH2CH2OSi), 38.7 (CH2CHCHCH2CH2OSi), 
56.0 (OCH3), 63.2 (CH2CHCHCH2CH2OSi), 71.3 (OCH2), 112.6 (C-2), 114.5 (C-5), 
120.4 (C-6), 127.3 (C-9), 127.7 (C-10), 128.1 (CH2 CHCH2CH2OSi), 128.5 (C-8), 
131.1 (CH2CHCHCH2CH2OSi), 134.2 (C-1), 137.5 (C-7), 146.5 (C-4), 149.7 (C-3). 
(Plate 23b) 
ER+-HRMS m/z: 435.2333 [M + Na]+  
                            (Calculated for C25H36O3Si+Na, 435.2331) 
IR νmax (cm





























To a solution of [(E)-5-(4-Benzyloxy-3-methoxyphenyl)pent-3-enoxy]-tert-butyl-
dimethylsilane  (124) (0.5 g, 1.21 mmol) in t-BuOH: H2O (1:1, 10 mL) was added AD-mix-α 
(1.8 g). This mixture was stirred at room temperature for 24 h. The reaction was quenched by 
adding sodium sulfite (2.0 g) and it was stirred for further 10 min. The reaction mixture was 
then extracted with EtOAc (3 x 10 mL), the combined organic layers were washed with 
aqueous 2N KOH solution, water, brine and dried over anhydrous MgSO4. The solvent was 
removed in vacuo and the purification of the crude product by flash chromatography afforded 
1-(4-Benzyloxy-3-methoxy phenyl)-5-(tert-butyl(methyl)silyl)oxypentane-2,3-diol (125) as a 
yellow oil (yield 0.498 g, 92%). 
 
1H NMR (400 MHz, CDCl3) δH: 0.10 (s, 6H, OSi(CH3)2C(CH3)3), 0.93 (s, 9H, 
OSi(CH3)2C(CH3)3), 1.65-1.92 (m, 2H, CH2CH(OH)CH(OH)CH2CH2O), 2.72-2.89 
(m, 2H, CH2CH(OH)CH(OH)CH2CH2O), 3.73 (d, 2H, J=34.4, 
CH2CH(OH)CH(OH)CH2CH2O), 5.14 (s, 2H, OCH2), 3.83-3.94 (m, 5H, OCH3, 
CH2CH(OH)CH(OH)CH2CH2O), 6.73 (d, 1H, J=8.2 Hz, H-5), 6.83-6.86 (m, 2H, H-2, 
H-6), 7.30-7.49 (m, 5H, Ar-H). (Plate 24a) 
13C NMR   (100 MHz, CDCl3) δC: -5.5 (OSi(CH3)2), 18.1 (OSi(CH3)2C(CH3)3), 25.8 
(OSi(CH3)2C(CH3)3), 35.4 (CH2CH(OH)CH(OH)CH2CH2OSi), 39.6 





(CH2CH(OH)CH(OH)CH2CH2OSi), 71.2 (CH2CH(OH)CH(OH)CH2CH2OSi), 72.8 
(CH2CH(OH)CH(OH)CH2CH2OSi), 75.2 (OCH2) 113.3 (C-2), 114.4 (C-5), 121.3 
(C-6), 127.3 (C-9), 127.7 (C-10), 128.5 (C-8), 131.8 (C-1), 137.4 (C-7), 146.8 (C-4), 
149.7 (C-3). (Plate 24b) 
ER+-HRMS m/z: 469.2384 [M + Na]+  
                           (Calculated for C25H38O5Si+Na, 469.2386) 
IR νmax (cm
-1): 3371 (OH), 1257 (C-O) 
 




















To a solution of 1-(4-Benzyloxy-3-methoxy phenyl)-5-(tert-butyl(methyl)silyl)oxypentane-
2,3-diol (125) (0.3 g, 0.6 mmol) in DCM ( 10 mL) at room temperature was added a Et3N 
(0.3 mL, 2.2 mmol) and acetic anhydride ( 0.2 mL, 2.2 mmol). This mixture was refluxed for 
6 h. After completion of the reaction as determined by TLC monitoring, the reaction mixture 
was diluted with water and extracted with Et2O (3 x 20 mL). The combined organic layers 
were washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo. The crude 
product was then purified using flash chromatography (8:2 hexane/EtOAc) to yield 5-(4-
Benzyloxy-3-methoxy phenyl)-1-[2-tert-butyl(dimethyl)silyl]oxypentane-2,3-diacetate (126) 






1H NMR (400 MHz, CDCl3) δH: 0.02 (s, 6H, O-Si(CH3)2C(CH3)3), 0.87 (s, 9H, O-
Si(CH3)2C(CH3)3), 1.74-1.86 (m, 2H, CH2CH(COOCH3)CH(COOCH3)CH2CH2O), 
2.01 (s, 3H, CH2CH(OOCH3)CH(OOCH3)), 2.12 (s, 3H, 
CH2CH(OOCH3)CH(OOCH3)), 2.71-2.86 (m, 2H, 
CH2CH(COOCH3)CH(COOCH3)CH2CH2O), 3.56-3.67 (m, 2H, 
CH2CH(COOCH3)CH(COOCH3)CH2CH2O), 3.88 (s, 3H, OCH3), 5.12 (s, 2H, OCH2), 
5.17-5.34 (m, 2H, CH2CH(COOCH3)CH(COOCH3)CH2CH2O), 6.67 (d, 1H, J = 8.4 
Hz, H-5), 6.75 (s, 1H, H-2), 6.80 (d,1H, J= 8.2 Hz, H-6)7.30-7.46 (m, 5H, Ar-H). 
(Plate 25a) 
13C NMR   (100 MHz, CDCl3) δC: -5.5 (OSi(CH3)2), 18.2 (OSi(CH3)2C(CH3)3), 20.9 
(OCOCH3), 25.8 (OSi(CH3)2C(CH3)3), 34.0 (CH2CH(Ac)CH(Ac)CH2CH2O), 
(CH2CH(Ac)CH(Ac)CH2CH2O), 56.1 (OCH3), 59.1 (CH2CH(Ac)CH(Ac)CH2CH2O), 
70.7 (CH2CH(Ac)CH(Ac)CH2CH2O), 70.9 (CH2CH(Ac)CH(Ac)CH2CH2O), 71.2 
(OCH2), 113.2 (C-2), 114.3 (C-5), 121.4 (C-6), 127.3 (C-9), 127.7 (C-10), 128.5 (C-8), 
129.9 (C-1), 136.1 (C-5), 149.6 (C-4),170.1 (OCOCH3), 170.2(OCOCH3) 
ER+-HRMS m/z: 553.2596 [M + Na]+  
(Calculated for C29H42O7Si+Na, 553.2598) 
 
























A solution of 2,3-[5-[(1,1-dimethylethyl)dimethylsilyloxy]-5-(4-benzyloxy-3-methoxy) 
phenyl]dihydroxypentane (125) (0.4 g, 0.9 mmol), DMP ( 0.2 mL, 1.7 mmol) and cat. 
P-TsOH in DCM (10 mL) was stirred at room temperature for 3 h. The reaction mixture was 
diluted with Et2O and washed with saturated NaHCO3 solution, water, brine, dried over 
anhydrous MgSO4 and concentrated in vacuo. The crude product was then purified using flash 
chromatography (8:2 hexane/EtOAc) to yield 2-[5-[(4-Benzyloxy-3-methoxyphenyl)methyl]-
2,2-dimethyl-1,3-dioxolan-4-yl]tert-butyldimethylsilane (138) as a colourless oil (yield 
0.35 g, 85%). 
 
1H NMR (400 MHz, CDCl3) δH: 0.01 (s, 6H, O-Si(CH3)2C(CH3)3), 0.86 (s, 9H, O-
Si(CH3)2C(CH3)3), 1.31 (s, 3H, CHO(C(CH3)2)OCH), 1.35 (s, 3H, 
CHO(C(CH3)2)OCH), 1.58 (q, 2H, J=6.1 Hz, CH2CHO(C(CH3)2)OCHCH2CH2O), 
2.74-2.87 (m, 2H, CH2CHO(C(CH3)2)OCHCH2CH2O), 3.62-3.73 (m, 2H, 
CH2CHO(C(CH3)2)OCHCH2CH2O), 3.75-3.88 (m, 2H, 
CH2CHO(C(CH3)2)OCHCH2CH2O), 3.85 (s, 2H, OCH3), 5.09 (s, 2H, OCH2), 6.67 (d, 
1H, J= 8.2 Hz, H-5), 6.76-6.79 (m, 2H, H-2 & H-6), 7.23-7.46 (m, 5H, Ar-H). 
(Plate 26a) 
13C NMR (100 MHz, CDCl3) δC: -5.36 (O-Si(CH3)2C(CH3)3), 18.3 18.1 
(OSi(CH3)2C(CH3)3), 25.9 (OSi(CH3)2C(CH3)3), 27.2 (CHO(C(CH3)2)OCH), 27.4 
CHO(C(CH3)2)OCH), 36.0(CH2CHO(C(CH3)2)OCHCH2CH2O) ,38.4 
(CH2CHO(C(CH3)2)OCHCH2CH2O), 56.0(OCH3), 59.9 
(CH2CHO(C(CH3)2)OCHCH2CH2O), 71.2(OCH2), 81.2 
(CH2CHO(C(CH3)2)OCHCH2CH2O), 108.1 (CHO(C(CH3)2)OCH), 113.5 (C-2), 114.2 
(C-5), 121.5 (C-6), 127.3 (C-9), 127.7 (C-10), 128.5 (C-8), 130.9 (C-1), 137.4 (C-7), 
146.9 (C-4), 149.5 (C-3). (Plate 26b) 
ER+-HRMS m/z: 509.2697 [M + Na]+  
                            (Calculated for C28H42O5Si+Na, 509.2699) 
IR νmax (cm






















To a solution of (E)-5-(4-benzyloxy-3-methoxyphenyl)pent-3-en-1-ol (117) (0.8 g, 2.7 mmol) 
in t-BuOH: H2O (1:1, 20 mL) was added AD-mix-α (1.0 g). This mixture was stirred at room 
temperature for 24 h. The reaction was quenched by adding sodium sulfite (1.00 g) and was 
stirred for further 10 min. The reaction mixture was extracted with EtOAc (3 x 10 mL), the 
combined organic layers were washed with aqueous 2N KOH solution, water, brine and dried 
over anhydrous MgSO4. The solvent was removed in vacuo and the purification of the crude 
product by flash chromatography (EtOAc) afforded 5-(4-Benzyloxy-3-
methoxy)phenyl]pentane-1,3,4-triol (131) as a white solid. (yield 0.79 g, 89% ) 
 
1H NMR (400 MHz, CDCl3) δH:  1.71-1.90 (m, 2H, 
CH2CH(OH)CH(OH)CH2CH2OH), 2.52 (br, OH), 2.63-3.11 (m, 2H, 
CH2CH(OH)CH(OH)CH2CH2OH), 3.64-3.80 (m, 2H, 
CH2CH(OH)CH(OH)CH2CH2OH),  3.81-3.93 (m,s, 5H 
CH2CH(OH)CH(OH)CH2CH2OH, OCH3), 5.13 (s, 2H, OCH2), 6.72 (d, 1H, J = 8.30 
Hz, H-5), 6.81 (s, 1H, H-2), 6.85 (d, J = 8.12 Hz, H-6), 7.30-7.47 (m, 5H, Ar-H). 
(Plate 27a) 
13C NMR (100 MHz, CDCl3) δC: 35.3 (CH2CH(OH)CH(OH)CH2CH2OH), 39.6 
(CH2CH(OH)CH(OH)CH2CH2OH), 56.1 (OCH3), 60.8 
(CH2CH(OH)CH(OH)CH2CH2OH), 71.2 (OCH2), 72.9 
(CH2CH(OH)CH(OH)CH2CH2OH), 75.2 (CH2CH(OH)CH(OH)CH2CH2OH), 113.3 
(C-2), 114.5 (C-5), 121.4 (C-6), 127.3 (C-9), 127.8 (C-10), 128.5 (C-8), 131.2 (C-1), 





ER+-HRMS m/z [M + Na]+:  
IR νmax (cm
-1): 3353-3539 (OH) 




















A solution of 2-[5-[(4-Benzyloxy-3-methoxyphenyl)methyl]-2,2-dimethyl-1,3-dioxolan-4-
yl] tert-butyldimethylsilane (138) (0.3 g, 0.6 mmol) and NH4F (0.1 g, 1.3 mmol) in dry MeOH 
was refluxed for 16 h. After completion of the reaction as determined by TLC monitoring, the 
reaction mixture was diluted with water and extracted with EtOAc (3 x 10 mL). The combined 
organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated in 
vacuo. The crude product was then purified using flash chromatography (5:5 hexane/EtOAc) 
to yield 2-[5-(4-Benzyloxy-3-methoxy)phenylmethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 
(132) as a yellow oil (yield 0.21 g, 90%). 
Method 2 
A solution of 5-(4-benzyloxy-3-methoxyphenyl)pentane-1,3,4-triol (131) (0.7 g, 2.1 mmol), 
DMP (0.4 mL, 3.2 mmol) and cat. P-TsOH in DCM (20 mL) was stirred at room temperature 
for 3 h. The reaction mixture was then diluted with Et2O and washed with saturated NaHCO3 
solution, water, brine, dried over anhydrous MgSO4 and concentrated in vacuo. The crude 





Benzyloxy-3-methoxy)phenylmethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol (132) as a 
yellow oil (yield 0.71 g, 90%). 
 
1H NMR (400 MHz, CDCl3) δH: 1.34 (s, 3H, CHO(C(CH3)2)OCH), 1.37 (s, 3H, 
CHO(C(CH3)2)OCH), 1.46-1.61 (m, 2H, CH2CHO(C(CH3)2)OCHCH2CH2O), 2.74 
(dd, 1H, CH2CHO(C(CH3)2)OCHCH2CH2O), 2.87-2.93 (m, 1H, 
CH2CHO(C(CH3)2)OCHCH2CH2O), 3.68 (t, 2H, J=5.6 Hz, 
CH2CHO(C(CH3)2)OCHCH2CH2O), 3.84 (s, 3H, OCH3), 3.86-3.91 (m, 2H, 
CH2CHO(C(CH3)2)OCHCH2CH2O), 5.10 (s, 2H, OCH2), 6.65 (d, 1H, J= 8.3 Hz, 
H-5), 6.74-6.80 (m, 2H, H-2 & H-6), 7.23-7.47 (m, 5H, Ar-H). (Plate 28a) 
13C NMR (100 MHz, CDCl3) δC: 27.3 (CHO(C(CH3)2)OCH), 34.8 
(CH2CHO(C(CH3)2)OCHCH2CH2OH), 38.6 (CH2CHO(C(CH3)2)OCHCH2CH2OH), 
56.0 (OCH3), 60.8 (CH2CHO(C(CH3)2)OCHCH2CH2OH), 71.2 (OCH2), 79.8 
(CH2CHO(C(CH3)2)OCHCH2CH2OH), 81.6 (CH2CHO(C(CH3)2)OCHCH2CH2OH), 
108.6 (CHO(C(CH3)2)OCH), 113.3 (C-2), 114.3 (C-5), 121.3 (C-6), 127.3 (C-9), 127.8 
(C-10), 128.5 (C-8), 130.4 (C-1), 137.3 (C-7), 146.8 (C-4), 149.7 (C-3). (Plate 28b) 
ER+-HRMS m/z: 395.1837 [M + Na]+  
                            (Calculated for C22H28O5+Na, 395.1834) 
IR νmax (cm





























To a stirred solution of 2-iodoxybenzoic acid (IBX) (0.8 g, 2.7 mmol) in DMSO (5 mL), was 
added a solution of alcohol 132 (0.5 g, 1.4 mmol) in THF (10 mL) at room temperature and 
was stirred for 3 hours. After completion of the reaction as observed by TLC monitoring, 
water (10 mL) was added to the reaction mixture and the precipitated solid was filtered off. 
The filtrate was diluted with water (10 mL) and extracted with Et2O (3 x 10 mL). The 
combined organic layers were washed successively with NaHCO3, water, brine and dried over 
anhydrous MgSO4. The solvent was removed in vacuo and the crude product was purified 
using column chromatography (7:3 hexane/EtOAc) to afford the desired product, 2-[5-(4-
benzyloxy-3-methoxy)phenylmethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]acetaldehyde (133) as a 
yellow oil (yield 0.45 g, 89%). 
1H NMR (400 MHz, CDCl3) δH: 1.41 (s, 6H, CHO(C(CH3)2)OCH), 2.21-2.28 (m, 1H, 
CH2CHO(C(CH3)2)OCHCH2COH),2.41-2.50(m,1H, 
CH2CHO(C(CH3)2)OCHCH2COH), 2.74-2.82 (m, 1H, 
CH2CHO(C(CH3)2)OCHCH2COH), 2.97-3.06 (m, 1H, J=5.6 Hz, 
CH2CHO(C(CH3)2)OCHCH2COH), 3.89 (s, 3H, OCH3), 3.89-3.96 (m, 2H, 
CH2CHO(C(CH3)2)OCHCH2COH), 4.13-4.20 (m, 1H), 5.14 (s, 2H, OCH2), 6.70 (d, 
1H, J= 8.3 Hz, H-5), 6.77-6.85 (m, 2H, H-2 & H-6), 7.28-7.48 (m, 5H, Ar-H), 9.71 (t, 





13C NMR (100 MHz, CDCl3) δC: 27.1 (CHO(C(CH3)2)OCH), 27.2 
(CHO(C(CH3)2)OCH) 38.4 (CH2CHO(C(CH3)2)OCHCH2COH), 46.6 
(CH2CHO(C(CH3)2)OCHCH2COH), 56.0(OCH3), 71.2 (OCH2), 75.7 
(CH2CHO(C(CH3)2)OCHCH2CH2O), 80.8 (CH2CHO(C(CH3)2)OCHCH2COH), 108.9 
(CHO(C(CH3)2)OCH), 113.2 (C-2), 114.4 (C-5), 121.3 (C-6), 127.3 (C-9), 127.8 (C-
10), 128.5 (C-8), 129.9 (C-1), 137.2 (C-7), 147.0 (C-4), 149.8 (C-3), 199.7 
(CH2CHO(C(CH3)2)OCHCH2COH). (Plate 29b) 
ER+-HRMS m/z: 393.1680 [M + Na]+  
    (Calculated mass for C22H26O5+Na, 393.1678) 
IR νmax (cm
-1): 1724 (C=O), 1259 (C-O) 
 
























2-[5-(4-Benzyloxy-3-methoxy)phenyl]-2,2-dimethyl-1,3-dioxolan-4-yl]acetaldehyde (0.5 g, 
1.3 mmol) (133) was dissolved in a mixture of (1:1) THF: 1N HCl (10 mL), this mixture was 
then stirred at room temperature for 12 h. After completion of the reaction as determined by 
TLC monitoring, the reaction mixture was diluted with water and extracted with Et2O (3 x 
5 mL). The combined organic layers were washed with brine, dried over anhydrous MgSO4 





(3:7 hexane/EtOAc) to yield    5-(4-Benzyloxy-3-methoxybenzyl)tetrahydrofuran-2,4-diol 
(137) as a yellow oil (yield 0.35 g, 85%). 
1H NMR (400 MHz, CDCl3) δH: 2.07-2.22 (m, 2H, H-1), 2.90-3.12 (m, 2H, H-4), 3.90 
(s, 3H, OCH3), 4.07-4.19 (m, 2H, H-2, H-3), 5.14 (s, 2H, OCH2), 5.52 (d, 1H, J= 4.7 
Hz, H-5), 6.75- 6.91 (m, 3H, Ph-H), 7.30- 7.47 (m, 5H, Ar-H). (Plate 30a) 
13C NMR (100 MHz, CDCl3) δC: 36.4 (C-1), 42.0 (C-4), 56.0 (OCH3), 71.2 (C-3), 71.6 
(OCH2), 85.8 (C-2), 98.7 (C-5), 113.2 (C-2’), 114.4 (C-5’), 121.1 (C-6’), 127.3 (C-9’), 
127.8 (C-10’), 128.5 (C-8’), 131.6 (C-1’), 137.4 (C-7’),  146.9 (C-4’), 149.7 (C-3’). 
(Plate 30b) 






















2-[5-(4-Benzyloxy-3-methoxy)phenyl]-2,2-dimethyl-1,3-dioxolan-4-yl]acetaldehyde (0.5 g, 
1.3 mmol) (133) was dissolved in MeOH with cat. amount of P-TsOH.  This mixture was then 
stirred at room temperature for 6 h. After completion of the reaction as determined by 
TLC monitoring, the reaction mixture was diluted with water and extracted with Et2O (3 x 
5 mL). The combined organic layers were washed with brine, dried over anhydrous MgSO4 
and concentrated in vacuo. The crude product was then purified using flash chromatography 
(3:7 hexane/EtOAc) to yield    5-(4-Benzyloxy-3-methoxybenzyl)tetrahydrofuran-2,4-diol 
(137) as a yellow oil (yield 0.35 g, 85%). 
1H NMR (400 MHz, CDCl3) δH: 2.14-2.22 (m, 2H, H-1), 3.20-3.23 (m, 2H, H-4), 3.22 
(s, 3H, OCH3), 3.80 (s, 3H, OCH3), 4.10-4.19 (m, 2H, H-2, H-3), 5.14 (s, 2H, OCH2), 





13C NMR (100 MHz, CDCl3) δC: 36.2 (C-1), 42.6 (C-4), 54.7 (OCH3), 56.0 (OCH3), 
71.7 (C-3), 71.9 (OCH2), 85.2 (C-2), 98.5 (C-5), 113.4 (C-2’), 114.7 (C-5’), 121.8 (C-
6’), 127.7 (C-9’), 127.4 (C-10’), 128.2 (C-8’), 131.7 (C-1’), 137.4 (C-7’),  146.9 (C-
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Plate 5b: 13C NMR spectrum for methyl 3,4,5-trihydroxybenzoate (99) 




























































































                                                                                                   





















   
 






























Plate 7b: 13C NMR spectrum for methyl 3-benzyloxy-4,5-dihydroxybenzoate (102) 




















































































































































































































































































































































Plate 10b: 13C NMR spectrum for 3-(benzyloxy)-4,5-dimethoxybenzaldehyde (105) 
 








































































































































































































































Plate 12b: 13C NMR spectrum for 2-(3-benzyloxy-4,5-dimethoxyphenyl)ethanol (107) 

















































































































Plate 13b: 13C NMR spectrum for 1-benzyloxy-5-(2-bromoethyl)-2,3-dimethoxybenzene (108) 



















                                                       



































































































































































































































Plate 15b: 13C NMR spectrum for 4-benzyloxy-3-methoxybenzaldehyde (110) 
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Plate 23a: 13H NMR spectrum for [(E)-5-(4-Benzyloxy-3-methoxyphenyl)pent-3-enoxy]-tert-butyl-imethylsilane  (124) 
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Plate 23b: 13C NMR spectrum for [(E)-5-(4-Benzyloxy-3-methoxyphenyl)pent-3-enoxy]-tert-butyldimethylsilane  (124) 































































Plate 24a: 1H NMR spectrum for 1-(4-Benzyloxy-3-methoxyphenyl)-5-(tert-butyl(methyl)silyl)oxypentane-2,3-diol (125) 
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Plate 24c: 1H NMR spectrum for 1-(4-Benzyloxy-3-methoxyphenyl)-5-(tert-butyl(methyl)silyl)oxypentane-2,3-diol (125) coordinated to 
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Plate 26a: 1H NMR spectrum for 2-[5-[(4-Benzyloxy-3-methox phenyl)methyl]-2,2-dimethyl-1,3-dioxolan-4-yl]tert-butyldimethylsilane (138) 
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Plate 26b: 13C NMR spectrum for 2-[5-[(4-Benzyloxy-3-methoxy phenyl)methyl]-2,2-dimethyl-1,3-dioxolan-4-yl]tert-butyl-dimethyl-silane 
(138) 




























      


























































     























Plate 27b: 13C NMR spectrum for 5-(4-benzyloxy-3-methoxy)phenyl]pentane-1,3,4-triol (131) 
















































































































































Plate 28b: 13C NMR spectrum for 2-[5-(4-Benzyloxy-3-methoxy)phenylmethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 
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Plate 30b: 13C NMR spectrum for 5-(4-Benzyloxy-3-methoxybenzyl)tetrahydrofuran-2,4-diol (137) 
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